{"gene":"TIMP1","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":1985,"finding":"TIMP-1 was sequenced from its cDNA and found to be identical to erythroid-potentiating activity (EPA), a glycoprotein that irreversibly forms inactive complexes with metalloproteinases. The protein consists of 184 amino acid residues with a 23-amino acid leader peptide, two N-linked oligosaccharide sites, and six disulfide bonds.","method":"cDNA cloning, protein sequencing, expression in E. coli and transfected animal cells","journal":"Nature / Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 1 — original sequence determination with protein sequencing validation, two independent labs","pmids":["3903517","3839290"],"is_preprint":false},{"year":1990,"finding":"The six disulfide bonds of human TIMP-1 were assigned: Cys1-Cys70, Cys3-Cys99, Cys13-Cys124, Cys127-Cys174, Cys132-Cys137, and Cys145-Cys166, defining the structural framework of the protein.","method":"Reverse-phase HPLC of proteolytic digests, reduction, Edman sequencing, and fast-atom-bombardment mass spectrometry","journal":"The Biochemical Journal","confidence":"High","confidence_rationale":"Tier 1 — direct structural determination with multiple orthogonal methods","pmids":["2163605"],"is_preprint":false},{"year":1997,"finding":"Crystal structure of the TIMP-1/MMP-3 (stromelysin-1) complex revealed that TIMP-1 occupies the entire active-site cleft of MMP-3 with its long edge; Cys1 bidentately coordinates the catalytic zinc of MMP-3, and the Thr2 side chain inserts into the large specificity pocket, defining the canonical wedge-shaped inhibitory mechanism.","method":"X-ray crystallography of MMP-3 catalytic domain complexed with TIMP-1","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional validation, foundational mechanistic paper","pmids":["9288970"],"is_preprint":false},{"year":1996,"finding":"TIMP-1 inhibits fibroblast collagenase (MMP-1) via a two-step noncompetitive mechanism: a rapidly formed reversible complex (Kd ~8 nM) slowly isomerizes into an extremely tight complex (global Kd ~0.1 nM). The C-terminal domain of collagenase is required for the initial rapid binding step; mini-collagenase lacking this domain forms only the simpler tight complex with lower affinity.","method":"Time-course kinetic analysis by graphic analysis, nonlinear regression of analytic integrals, and numeric integration of rate equations; comparison with truncated mini-collagenase","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — rigorous in vitro kinetic analysis with multiple analytical methods and mutagenesis-equivalent domain deletion","pmids":["8798626"],"is_preprint":false},{"year":1998,"finding":"NMR and paramagnetic surface probing mapped the TIMP-1/MMP-3 interface in solution: TIMP-1 protects MMP-3 residues Tyr155, Asn162, Val163, Leu164, His166, Ala167, Ala169, and Phe210 from Gd-EDTA broadening, consistent with the crystal structure. N-TIMP-1 binding also induces conformational changes in MMP-3 helix C (Asp238, Asn240, Gly241, Ser244) and alters hydrogen bonding near the active site, confirming N-terminal displacement in solution.","method":"NMR amide proton line-broadening with paramagnetic Gd-EDTA probe, hydrogen exchange assays","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — NMR structural mapping in solution corroborated by crystal structure","pmids":["9657677"],"is_preprint":false},{"year":2000,"finding":"TIMP-1 inhibits ADAM-10 with an apparent inhibition constant of ~0.1 nM, whereas TIMP-2 and TIMP-4 cannot inhibit ADAM-10; TIMP-3 inhibits ADAM-10 with Ki ~0.9 nM. This selectivity distinguishes ADAM-10 from TACE (ADAM-17), which is inhibited only by TIMP-3, providing a tool to differentiate the two sheddases in cell-based assays.","method":"Quenched fluorescent substrate assay and myelin basic protein degradation assay with recombinant ADAM-10 Fc fusion protein","journal":"FEBS Letters","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic assay with quantitative Ki determination, replicated with two substrates","pmids":["10818225"],"is_preprint":false},{"year":2008,"finding":"The full-length N-terminal domain of TIMP-1 (N-TIMP-1) alone is insufficient to inhibit ADAM-10, in contrast to its inhibition of MMPs and ADAM-17 by TIMP-3 N-terminal domain; the C-terminal domain of TIMP-1 (or structural context beyond the N-terminal domain alone) is required for ADAM-10 inhibition.","method":"Inhibition assays comparing full-length TIMPs vs. isolated N-terminal domains against ADAM-10, ADAM-17, and MMPs","journal":"The Biochemical Journal","confidence":"High","confidence_rationale":"Tier 1 — systematic in vitro inhibition assays with domain-deletion variants","pmids":["18215140"],"is_preprint":false},{"year":1996,"finding":"TIMP-1 (and TIMP-2) stimulate cell proliferation via tyrosine kinase-dependent signaling: tyrosine kinase inhibitors (genistein, erbstatin, herbimycin A) block TIMP-1-induced [3H]thymidine incorporation, while PKC and PKA inhibitors do not; TIMP-1 treatment elevates phosphotyrosine-containing proteins and activates MAP kinase, establishing a growth-signaling pathway independent of MMP inhibition.","method":"[3H]Thymidine incorporation, selective kinase inhibitors, phosphotyrosine immunoblotting, MAP kinase activity assay in MG-63 osteosarcoma cells","journal":"FEBS Letters","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal pharmacological and biochemical methods in one study","pmids":["8906876"],"is_preprint":false},{"year":2002,"finding":"TIMP-1 activates Ras (increases Ras-GTP) via a tyrosine kinase (TYK)/MAPK pathway (herbimycin A-sensitive), whereas TIMP-2 activates Ras through a PKA-mediated pathway (H89-sensitive); the two TIMPs thus use distinct upstream signaling routes to reach a common Ras effector, with TIMP-2 also promoting Ras-GTP/PI3K complex formation.","method":"Ras-GTP pull-down assay, selective kinase inhibitors (herbimycin A, H89) in MG-63 cells","journal":"Biochemical and Biophysical Research Communications","confidence":"Medium","confidence_rationale":"Tier 2 — biochemical pull-down and pharmacological dissection; single lab","pmids":["12147251"],"is_preprint":false},{"year":2002,"finding":"TIMP-1 inhibits apoptosis of activated hepatic stellate cells (HSCs) via MMP inhibition: a T2G mutant of TIMP-1 (selectively ablates MMP inhibitory activity) fails to prevent apoptosis, and synthetic MMP inhibitors also block HSC apoptosis, placing MMP inhibition upstream of the anti-apoptotic effect in HSCs.","method":"Site-directed mutagenesis (T2G mutant), synthetic MMP inhibitor treatment, apoptosis assays (serum deprivation, cycloheximide, nerve growth factor) in cultured HSCs and in vivo fibrosis model","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis with functional apoptosis readout, corroborated in vivo","pmids":["11796725"],"is_preprint":false},{"year":2003,"finding":"TIMP-1 activates cell survival signaling in human breast epithelial cells via focal adhesion kinase (FAK), PI3K, and ERK pathways independent of MMP inhibition: the T2G MMP-inactive mutant retains anti-apoptotic activity, synthetic MMP inhibitors do not protect these cells, and TIMP-1 still enhances survival in the presence of synthetic MMP inhibitors, revealing a cell-type-specific, MMP-independent signaling mechanism.","method":"T2G mutant, synthetic MMP inhibitor, TIMP-1 knockdown/overexpression, kinase pathway inhibitors, caspase activity assays in MCF10A breast epithelial cells","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — mutagenesis, pharmacological dissection, and loss-of-function with defined molecular readouts","pmids":["12904305"],"is_preprint":false},{"year":2006,"finding":"CD63, a tetraspanin, was identified as a TIMP-1 cell-surface binding partner by yeast two-hybrid screening, confirmed by co-immunoprecipitation and confocal microscopy. CD63 co-localizes with TIMP-1 and integrin β1 on the cell surface; shRNA knockdown of CD63 reduces TIMP-1 cell-surface binding, abrogates TIMP-1-mediated integrin β1 activation and cell survival signaling, and restores normal polarization of breast epithelial cells in 3D matrigel, establishing CD63 as the functional receptor mediating TIMP-1's MMP-independent cytokine-like effects.","method":"Yeast two-hybrid, co-immunoprecipitation, confocal microscopy, shRNA knockdown, 3D matrigel polarization assay, integrin activation assays","journal":"The EMBO Journal","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including Y2H, Co-IP, imaging, and functional KD with defined phenotype","pmids":["16917503"],"is_preprint":false},{"year":2008,"finding":"TIMP-1's anti-apoptotic signaling in erythroid (UT-7) cells requires formation of a ternary complex: TIMP-1 binds specifically to proMMP-9 at the cell surface (silencing proMMP-9 abrogates TIMP-1 signaling), and proMMP-9 is anchored to the plasma membrane by CD44. The anti-apoptotic effect is MMP-independent (MMP-9-blocking antibodies and synthetic MMP inhibitors cannot replicate it), but these agents prevent TIMP-1 binding to proMMP-9, abolishing downstream JAK2/PI3K/Akt survival signaling.","method":"siRNA knockdown of proMMP-9 and CD44, function-blocking antibodies, synthetic MMP inhibitor, flow cytometry, binding/co-localization assays in UT-7 erythroid cells","journal":"The International Journal of Biochemistry & Cell Biology","confidence":"High","confidence_rationale":"Tier 2 — multiple loss-of-function approaches with mechanistic epistasis establishing ternary complex requirement","pmids":["19010442"],"is_preprint":false},{"year":2001,"finding":"The MMP-9·TIMP-1 complex binds LRP (low-density lipoprotein receptor-related protein) with high affinity, and LRP mediates cellular internalization and catabolism of MMP-9·TIMP-1 complexes; cells genetically deficient in LRP show diminished capacity for MMP-9·TIMP-1 catabolism, revealing LRP as a clearance receptor for the TIMP-1/MMP-9 complex.","method":"RAP (receptor-associated protein) antagonism, 125I-labeling internalization assays, LRP-deficient cell lines, in vitro binding assays","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — biochemical binding assays plus genetic loss-of-function with quantitative internalization readout","pmids":["11279011"],"is_preprint":false},{"year":2005,"finding":"In liver regeneration, TIMP-1 negatively regulates hepatocyte cell cycle progression by limiting HGF bioavailability: TIMP-1 loss-of-function (Timp-1−/− mice) accelerates expression of cyclin D1, PCNA, and phospho-histone H3, elevates MMP activity, increases active HGF in the ECM, and enhances phospho-Met and p38 signaling; conversely, TIMP-1 gain-of-function delays cell cycle progression.","method":"Timp-1−/− and transgenic overexpressing mice, real-time RT-PCR, HGF activity assays, immunostaining of cell cycle markers, partial hepatectomy model","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 2 — genetic gain- and loss-of-function with defined molecular mechanism (HGF/Met pathway)","pmids":["15726641"],"is_preprint":false},{"year":2011,"finding":"Tumor cell-derived TIMP-1 maintains pro-metastatic Met signaling by inhibiting ADAM-10-mediated Met shedding: knockdown of tumor cell Timp-1 suppresses Met phosphorylation in metastatic foci and inhibits metastasis formation; conversely, knockdown of ADAM-10 triggers Met auto-phosphorylation and increased responsiveness to HGF, phenocopying Timp-1 overexpression.","method":"siRNA knockdown of Timp-1 and Adam-10 in syngeneic murine liver metastasis model, Met phosphorylation assays, HGF stimulation assays, tumor cell scattering assay","journal":"Clinical & Experimental Metastasis","confidence":"High","confidence_rationale":"Tier 2 — reciprocal epistasis knockdown experiments with defined molecular pathway in vivo and in vitro","pmids":["21789719"],"is_preprint":false},{"year":2011,"finding":"TIMP-1 secreted by astrocytes promotes oligodendrocyte precursor cell (OPC) differentiation and CNS myelination via a mechanism independent of MMP inhibition: recombinant TIMP-1 increases NG2+ OPC numbers and O1+ mature oligodendrocyte numbers in a dose-dependent fashion, whereas the broad-spectrum MMP inhibitor GM6001 does not replicate this effect; TIMP-1 KO mice show delayed myelination and reduced white matter astrocytes.","method":"TIMP-1 KO mice, neurosphere cultures, A2B5+ immunopanned OPCs, recombinant TIMP-1 treatment, anti-TIMP-1 antisera, MMP inhibitor control (GM6001), developmental histology","journal":"The Journal of Neuroscience","confidence":"High","confidence_rationale":"Tier 2 — KO mouse, recombinant protein rescue, neutralizing antibody, and MMP-inhibitor control establishing MMP-independence","pmids":["21508247"],"is_preprint":false},{"year":2014,"finding":"TIMP-1 acts as a chemoattractant for human neural stem cells (hNSCs) via CD63 and β1 integrin signaling: TIMP-1 binding to CD63 activates β1 integrin-mediated Akt and FAK phosphorylation and cytoskeletal reorganization; shRNA-mediated CD63 knockdown or β1 integrin blocking antibody abrogates TIMP-1-induced focal adhesion formation and migration.","method":"Microarray/proteomics identification, shRNA knockdown of CD63, β1-integrin blocking antibody, PI3K inhibition, focal adhesion and F-actin imaging, Boyden chamber migration assay","journal":"The Biochemical Journal","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal loss-of-function approaches with defined signaling readouts","pmids":["24635319"],"is_preprint":false},{"year":2015,"finding":"TIMP-1-mediated signaling via CD63 is necessary and sufficient to induce granulopoiesis and neutrophilia in mice: TIMP-1 variants that dissociate protease-inhibitory activity from CD63 binding reveal that the CD63-binding signaling domain alone drives bone marrow myeloid progenitor expansion and granulopoiesis; CD63 ablation abolishes both neutrophilia and TIMP-1-enhanced granulopoiesis.","method":"Systemic TIMP-1 elevation in mice, TIMP-1 domain-dissecting variants, BrdU pulse-labeling, CD63-null mice, bone marrow granulopoiesis-associated gene expression","journal":"Haematologica","confidence":"High","confidence_rationale":"Tier 2 — genetic receptor ablation and domain-dissecting variants with in vivo phenotypic readout","pmids":["26001794"],"is_preprint":false},{"year":2015,"finding":"TIMP-1 mediates TGF-β-dependent crosstalk between hepatic stellate cells and HCC cells via FAK signaling downstream of its receptor CD63: TGF-β signaling in HSCs induces TIMP-1 secretion; TIMP-1 then activates FAK via CD63 on HCC cells, promoting their proliferation, motility, and survival; inhibition of TGF-β signaling (EW-7197) blocks TIMP-1 secretion and downstream FAK/Akt activation.","method":"Secreted protein identification from HSCs, CD63 interaction studies, FAK phosphorylation assays, orthotopic xenograft mouse model, pharmacological TGF-β receptor inhibition","journal":"Scientific Reports","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway placement with in vivo validation; single lab","pmids":["26549110"],"is_preprint":false},{"year":2018,"finding":"TIMP-1 promotes oligodendrocyte differentiation via a CD63/β1-integrin/Akt/β-catenin signaling axis: recombinant TIMP-1 activates Akt and stabilizes β-catenin in OPCs in a CD63- and β1-integrin-dependent manner; this trophic action is independent of TIMP-1's MMP-inhibitory function and is counteracted (but not abrogated) by Wnt7a-mediated canonical Wnt signaling.","method":"Recombinant TIMP-1 treatment of OPCs, CD63/β1-integrin blocking, Akt inhibitors, β-catenin reporter assays, Wnt7a co-treatment","journal":"Molecular Neurobiology","confidence":"Medium","confidence_rationale":"Tier 2 — receptor blocking and pathway inhibition with defined differentiation readout; single lab","pmids":["30121936"],"is_preprint":false},{"year":2011,"finding":"BRAFV600E drives TIMP-1 upregulation via NF-κB activation in papillary thyroid carcinoma: BRAF silencing in BCPAP cells decreases TIMP-1 expression and NF-κB binding activity; TIMP-1 then binds its surface receptor CD63, leading to Akt phosphorylation and anti-apoptotic/pro-invasive behavior. The BRAF→NF-κB→TIMP-1→CD63→Akt signaling axis is MEK-independent (sorafenib but not MEK inhibitors reduce TIMP-1 and Akt phosphorylation).","method":"BRAF gene silencing, specific MAPK/NF-κB inhibitors, TIMP-1 expression analysis, Akt phosphorylation assays, invasion assay in BCPAP cells","journal":"Endocrine-Related Cancer","confidence":"Medium","confidence_rationale":"Tier 2 — genetic silencing and pharmacological dissection with defined pathway; single lab","pmids":["21903858"],"is_preprint":false},{"year":2012,"finding":"TIMP-1 promotes cell survival in breast cancer via a CD63/NOS2 pathway: TIMP-1 protein nitration and TIMP-1/CD63 co-immunoprecipitation occur at NO concentrations that induce PI3K/Akt/BAD pro-survival signaling; TIMP-1 antisense silencing blocks NO-induced PI3K/Akt/BAD phosphorylation in MDA-MB-231 cells.","method":"Antisense knockdown, co-immunoprecipitation of TIMP-1/CD63, immunohistochemistry, phosphorylation assays","journal":"PLoS One","confidence":"Medium","confidence_rationale":"Tier 2–3 — Co-IP and loss-of-function with defined signaling readout; single lab","pmids":["22957045"],"is_preprint":false},{"year":2021,"finding":"CD74 (invariant chain) was identified as a functional receptor for TIMP-1: co-immunoprecipitation and confocal microscopy confirmed TIMP-1-CD74 interaction; in silico docking (HADDOCK) predicted the N-terminal domain of TIMP-1 (N-TIMP-1) as the CD74 binding region, experimentally confirmed by showing recombinant N-TIMP-1 alone binds CD74; TIMP-1-CD74 interaction triggers intracellular ZAP-70 activation, and a synthetic peptide targeting the CD74 cytokine-binding site abrogates this activation.","method":"Ligand-receptor capture screening, co-immunoprecipitation, confocal microscopy, in silico docking (HADDOCK), recombinant N-TIMP-1 domain, ZAP-70 phosphorylation assays, blocking peptide","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — unbiased receptor screen confirmed by Co-IP, domain mapping, in silico docking, and functional signaling readout with blocking peptide","pmids":["34391782"],"is_preprint":false},{"year":2023,"finding":"TIMP-1 interacts with Amyloid Precursor Protein (APP) and Amyloid Precursor-like Protein-2 (APLP2) as a novel receptor pair: unbiased ligand-receptor capture screening revealed this interaction, confirmed by pull-down assays and confocal microscopy; TIMP-1 triggers glucose uptake and proinflammatory cytokine expression in human monocytes via its C-terminal domain and through APP, establishing APP as a TIMP-1 receptor mediating proinflammatory monocyte activation.","method":"Unbiased ligand-receptor capture screening, pull-down assays, confocal microscopy, in silico docking, recombinant TIMP-1 C-terminal domain variants, glucose uptake assays, cytokine expression assays","journal":"The Journal of Cell Biology","confidence":"High","confidence_rationale":"Tier 2 — unbiased screen confirmed by multiple orthogonal assays with functional domain mapping","pmids":["36629908"],"is_preprint":false},{"year":2023,"finding":"ADAMTS-7 directly degrades TIMP-1: in coimmunoprecipitation experiments the catalytic domain of ADAMTS-7 binds TIMP-1, which is degraded by ADAMTS-7 in vitro; ADAMTS-7 reduces TIMP-1's inhibitory capacity toward MMP-9, increasing net MMP-9 activity and collagen degradation in atherosclerotic plaques; Apoe−/−Adamts7−/− mice accumulate more Timp-1 and more collagen than Apoe−/− controls.","method":"Mass spectrometry of atherosclerotic plaques (Apoe−/−Adamts7−/− vs Apoe−/− mice), coimmunoprecipitation, in vitro degradation assays, FRET-based protein-protein interaction assay, immunofluorescence, picrosirius red staining","journal":"Circulation Research","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro degradation assay, Co-IP, FRET, and genetic mouse model with ECM readout","pmids":["37675562"],"is_preprint":false},{"year":2000,"finding":"The human TIMP-1 gene contains transcriptional repressive elements: a region upstream of the basal promoter (−1718/−1458) represses reporter gene expression by ~50%, and the first intron strongly represses transcription from any promoter; deletion analysis and protein binding/mutational studies identified a repressive element at intron +684/+748 that binds Sp1, Sp3, and an unidentified Ets-related factor.","method":"Reporter gene constructs, deletion analysis, electrophoretic mobility shift assay (EMSA), mutational analysis, protein binding studies","journal":"The Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — functional promoter dissection with EMSA and mutational confirmation","pmids":["11032844"],"is_preprint":false},{"year":2002,"finding":"Thrombin induces TIMP-1 gene transcription in human mesangial cells via STAT1 and STAT3: thrombin-induced STAT-DNA binding and TIMP-1 mRNA elevation are both blocked by STAT1 and STAT3 antisense oligonucleotides; supershift assays confirm STAT1 and STAT3 proteins are in the thrombin-induced DNA-binding complex.","method":"Northern blot, EMSA, supershift assay, antisense oligonucleotides in human glomerular mesangial cells","journal":"Kidney International","confidence":"Medium","confidence_rationale":"Tier 2 — antisense knockdown of transcription factors with EMSA confirmation of DNA binding","pmids":["11918744"],"is_preprint":false},{"year":2013,"finding":"TIMP-1 expression is a direct target of miR-1293: luciferase reporter assay with wild-type and mutant TIMP-1 3′UTR constructs showed miR-1293 inhibitor upregulates reporter activity; Western blot confirmed elevated TIMP-1 protein with miR-1293 inhibitor, establishing direct post-transcriptional regulation of TIMP-1 by miR-1293.","method":"Luciferase reporter assay with wild-type and mutant 3′UTR, Western blot, miR-1293 mimic and inhibitor co-transfection in 293T cells","journal":"Molecular and Cellular Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — direct 3′UTR luciferase assay with mutant control and protein-level validation","pmids":["23943285"],"is_preprint":false},{"year":2014,"finding":"TIMP-1 induces pro-tumorigenic miR-210 upregulation in lung adenocarcinoma cells via a CD63/PI3K/Akt/HIF-1α-dependent pathway: TIMP-1 induces PI3K p110/p85 signaling and Akt phosphorylation, elevates HIF-1α protein, and upregulates HIF-1-regulated miR-210; downstream targets of miR-210 (FGFRL1, E2F3, VMP-1, RAD52, SDHD) are decreased; TIMP-1-containing exosomes accumulate miR-210 and promote HUVEC tube formation.","method":"Exogenous TIMP-1 treatment and TIMP-1 overexpression, PI3K/Akt inhibitors, HIF-1α monitoring, miR-210 quantification, target gene expression, exosome isolation and functional tube formation assay, in vivo xenograft","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — multiple pathway inhibition experiments with in vitro and in vivo validation","pmids":["25263437"],"is_preprint":false},{"year":2013,"finding":"TIMP-1 promotes cancer-associated fibroblast (CAF) accumulation and activates ERK1/2 signaling in prostate CAFs: TIMP-1 overexpression in xenograft models increases in vivo tumor growth and CAF accumulation; recombinant TIMP-1 enhances prostate CAF proliferation, migration, and ERK1/2 phosphorylation in vitro.","method":"TIMP-1 overexpressing constructs in xenograft mouse models (prostate and colon cancer), in vitro CAF proliferation/migration assays, ERK1/2 phosphorylation assays","journal":"PLoS One","confidence":"Medium","confidence_rationale":"Tier 2 — gain-of-function in vivo and in vitro with defined kinase readout; single lab","pmids":["24143225"],"is_preprint":false},{"year":2016,"finding":"TIMP-1 promotes colon cancer cell proliferation and metastasis via FAK-PI3K/AKT and MAPK signaling: TIMP-1 suppression decreases proliferation and metastasis while increasing apoptosis; mechanistic analyses confirm these effects are mediated through TIMP-1-specific regulation of FAK-PI3K/AKT and MAPK pathways in colon cancer cell lines.","method":"TIMP-1 knockdown and overexpression, proliferation/apoptosis/metastasis assays in vitro and in vivo (xenograft), FAK/Akt/MAPK phosphorylation assays, clinical specimen analysis (94 colon cancer cases)","journal":"Journal of Experimental & Clinical Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 — loss- and gain-of-function with mechanistic pathway analysis; single lab","pmids":["27644693"],"is_preprint":false},{"year":2013,"finding":"TIMP-1 reduces angiogenesis by restricting TIMP-1-free proMMP-9: in M2-polarized macrophages, downregulation of TIMP-1 produces TIMP-1-free proMMP-9 that is strongly angiogenic; re-complexing M2 proMMP-9 with exogenous TIMP-1 abolishes angiogenic activity; TIMP-1 silencing in M0/M1 macrophages renders them angiogenic; Mmp9-null M2 macrophages are nonangiogenic despite low TIMP-1.","method":"Macrophage polarization (M0/M1/M2), TIMP-1 ELISA, TIMP-1 siRNA silencing, in vivo angiogenesis assay, Mmp9-null murine macrophages, proMMP-9 reconstitution with exogenous TIMP-1","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal loss-of-function and reconstitution experiments with in vivo angiogenesis readout","pmids":["24174628"],"is_preprint":false},{"year":1993,"finding":"TIMP-1 inhibits stimulated bone resorption in a dose-dependent and reversible manner in vitro: recombinant TIMP-1 (and TIMP-2) blocked both PTH- and 1,25-dihydroxyvitamin D3-induced bone resorption in neonatal mouse calvarial cultures, without affecting protein synthesis, DNA synthesis, or cell viability markers.","method":"Neonatal mouse calvarial culture, PTH and vitamin D3 stimulation, dose-response with recombinant TIMPs, reversibility experiments","journal":"Biochimica et Biophysica Acta","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro assay with dose-response and reversibility control","pmids":["8485170"],"is_preprint":false},{"year":2004,"finding":"TIMP-1 inhibits endothelial cell migration through both MMP-dependent and MMP-independent mechanisms: MMP-dependent inhibition involves upregulation of VE-cadherin and PECAM-1 at cell-cell junctions; MMP-independent inhibition involves stimulation of PTEN expression with subsequent dephosphorylation of FAK (pY397) and paxillin, reduced F-actin stress fibers, and fewer focal adhesions.","method":"HDMVEC migration assay, synthetic MMP inhibitors (GM6001, MMP-2/9 inhibitor III), recombinant TIMP-1, VE-cadherin/PECAM-1/FAK/paxillin/PTEN immunostaining, F-actin cytoskeleton analysis","journal":"Experimental Cell Research","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic dissection of MMP-dependent vs independent pathways with multiple molecular readouts","pmids":["15530852"],"is_preprint":false},{"year":2019,"finding":"TIMP-1 inhibits proliferation and osteogenic differentiation of human bone marrow MSCs through the Wnt/β-catenin signaling pathway: TIMP-1 knockdown upregulates β-catenin and cyclin D1 and promotes osteogenesis; TIMP-1 overexpression attenuates Wnt3a-induced upregulation of cyclin D1 and RUNX-2, while TIMP-1 knockdown restores Dkk1-inhibited β-catenin and cyclin D1 expression.","method":"Stable TIMP-1 overexpression and knockdown in hBMSCs, osteogenic differentiation assays (Alizarin Red, ALP activity, qPCR), β-catenin/cyclin D1/RUNX-2 Western blotting, Wnt3a and Dkk1 epistasis experiments","journal":"Bioscience Reports","confidence":"Medium","confidence_rationale":"Tier 2 — genetic gain- and loss-of-function with pathway epistasis; single lab","pmids":["30473539"],"is_preprint":false},{"year":2004,"finding":"EGF-induced secretion of TIMP-1 (and MMP-9) in extravillous trophoblasts requires activation of both PI3K and MAPK pathways: PI3K inhibitor LY294002 blocks Akt phosphorylation and abrogates TIMP-1 induction without affecting ERK; MEK inhibitor U0126 blocks ERK phosphorylation without affecting Akt; constitutively active Akt alone is insufficient to induce TIMP-1 secretion, placing TIMP-1 induction downstream of both pathways acting in parallel.","method":"PI3K inhibitor (LY294002), MEK inhibitor (U0126), constitutively active Akt constructs, RT-PCR, Western blot, zymography in HTR8/SVneo trophoblast cells","journal":"Reproduction","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological pathway dissection with genetic epistasis (constitutively active Akt)","pmids":["15333786"],"is_preprint":false}],"current_model":"TIMP-1 is a two-domain secreted glycoprotein that inhibits virtually all MMPs and selected ADAMs (notably ADAM-10 but not ADAM-17) by inserting its N-terminal wedge-shaped edge into the MMP active-site cleft with Cys1 bidentately coordinating the catalytic zinc (Ki sub-nM, two-step slow tight-binding mechanism); independent of MMP inhibition, TIMP-1 acts as a cytokine via multiple cell-surface receptor complexes—including CD63/integrin β1 (activating FAK, PI3K/Akt, and ERK survival pathways), proMMP-9/CD44 (erythroid survival), CD74 (triggering ZAP-70 for proinflammatory monocyte activation), and APP/APLP2 (monocyte glucose uptake)—while upstream ADAMTS-7 can proteolytically degrade TIMP-1 to derepress MMP-9 activity, and intracellular TIMP-1 levels are regulated post-transcriptionally by miR-1293 and transcriptionally by an intron-1 repressive element binding Sp1/Sp3/Ets factors, STAT1/STAT3 (thrombin-induced), and NF-κB (TNFα/IL-6/BRAFV600E-induced)."},"narrative":{"teleology":[{"year":1985,"claim":"Molecular cloning resolved TIMP-1's primary structure and established its identity with erythroid-potentiating activity (EPA), unifying two previously separate biological activities under one gene product.","evidence":"cDNA cloning and protein sequencing by two independent laboratories","pmids":["3903517","3839290"],"confidence":"High","gaps":["No three-dimensional structure available","Mechanism of metalloproteinase inhibition unknown","Receptor for EPA activity unidentified"]},{"year":1990,"claim":"Assignment of all six disulfide bonds defined the covalent framework that constrains the two-domain architecture critical for TIMP-1 function.","evidence":"Reverse-phase HPLC of proteolytic digests with Edman sequencing and FAB-MS","pmids":["2163605"],"confidence":"High","gaps":["Three-dimensional fold unknown","Functional roles of individual disulfides not tested"]},{"year":1996,"claim":"Kinetic analysis revealed TIMP-1 inhibits MMP-1 via a two-step slow tight-binding mechanism—a rapid initial complex (Kd ~8 nM) isomerizes to an extremely tight form (global Kd ~0.1 nM)—and showed the MMP C-terminal hemopexin domain is required for the fast first step.","evidence":"Time-course kinetic analysis with graphic, nonlinear regression, and numeric integration methods; comparison with truncated mini-collagenase","pmids":["8798626"],"confidence":"High","gaps":["Structural basis of isomerization step unknown","Generality to other MMPs not tested"]},{"year":1997,"claim":"The crystal structure of TIMP-1/MMP-3 revealed the canonical wedge-shaped inhibitory mechanism: Cys1 bidentately coordinates the catalytic zinc while Thr2 occupies the specificity pocket, explaining how a single inhibitor blocks diverse MMPs.","evidence":"X-ray crystallography of MMP-3 catalytic domain complexed with TIMP-1","pmids":["9288970"],"confidence":"High","gaps":["Conformational dynamics in solution not captured","Basis of TIMP selectivity among MMPs incompletely explained"]},{"year":1998,"claim":"NMR-based solution mapping confirmed the crystallographic TIMP-1/MMP-3 interface and additionally revealed allosteric conformational changes in MMP-3 helix C upon TIMP-1 binding, extending the inhibitory model beyond the active site.","evidence":"NMR amide proton line-broadening with paramagnetic Gd-EDTA probe and hydrogen exchange assays","pmids":["9657677"],"confidence":"High","gaps":["Functional significance of allosteric changes in MMP-3 helix C untested","Full-length TIMP-1 vs N-TIMP-1 comparison not performed"]},{"year":1996,"claim":"TIMP-1 was shown to signal as a growth factor—activating tyrosine kinase, MAP kinase, and phosphotyrosine cascades independently of MMP inhibition—establishing its dual identity as both protease inhibitor and cytokine.","evidence":"Thymidine incorporation, selective kinase inhibitors, phosphotyrosine immunoblotting, MAP kinase activity assay in MG-63 cells","pmids":["8906876"],"confidence":"High","gaps":["Cell-surface receptor unknown","MMP-independence not yet proven by mutagenesis"]},{"year":2000,"claim":"Extending TIMP-1's inhibitory range beyond MMPs, quantitative enzymology showed TIMP-1 inhibits ADAM-10 at sub-nanomolar Ki but not ADAM-17, distinguishing these two sheddases pharmacologically.","evidence":"Quenched fluorescent substrate assay and MBP degradation assay with recombinant ADAM-10","pmids":["10818225"],"confidence":"High","gaps":["Structural basis for ADAM-10 selectivity unknown","Domain requirements for ADAM-10 inhibition untested"]},{"year":2001,"claim":"LRP was identified as a clearance receptor for MMP-9·TIMP-1 complexes, providing a mechanism for systemic catabolism of the inhibitor–enzyme pair.","evidence":"125I-labeling internalization assays, RAP antagonism, and LRP-deficient cell lines","pmids":["11279011"],"confidence":"High","gaps":["Whether free TIMP-1 also binds LRP unclear","In vivo significance for TIMP-1 levels not demonstrated"]},{"year":2002,"claim":"The T2G mutant (MMP-inactive) demonstrated that TIMP-1's anti-apoptotic effect in hepatic stellate cells is MMP-dependent, while in breast epithelial cells it is MMP-independent, revealing cell-type-specific signaling modes.","evidence":"T2G mutagenesis, synthetic MMP inhibitor comparison, apoptosis assays in HSCs and MCF10A cells; corroborated in vivo","pmids":["11796725","12904305"],"confidence":"High","gaps":["Receptor mediating MMP-independent signaling in breast epithelial cells unknown at this point","Structural determinants of the cytokine-like surface not mapped"]},{"year":2005,"claim":"Genetic gain- and loss-of-function in mice revealed TIMP-1 negatively regulates hepatocyte cell cycle progression during liver regeneration by limiting HGF bioavailability through MMP inhibition.","evidence":"Timp-1−/− and transgenic overexpressing mice, partial hepatectomy, HGF activity assays, cell cycle marker immunostaining","pmids":["15726641"],"confidence":"High","gaps":["Which specific MMPs cleave pro-HGF in this context not identified","Whether TIMP-1's cytokine function also contributes unclear"]},{"year":2006,"claim":"CD63 was identified as the cell-surface receptor for TIMP-1's MMP-independent signaling: CD63 knockdown abolished TIMP-1 binding, integrin β1 activation, cell survival, and epithelial polarization, establishing the CD63/β1-integrin axis.","evidence":"Yeast two-hybrid, co-immunoprecipitation, confocal microscopy, shRNA knockdown, 3D matrigel assay","pmids":["16917503"],"confidence":"High","gaps":["Direct binding site on TIMP-1 for CD63 not mapped","Stoichiometry of CD63/integrin β1/TIMP-1 complex undefined"]},{"year":2008,"claim":"A distinct ternary receptor complex—proMMP-9/CD44—was shown to mediate TIMP-1's anti-apoptotic signaling in erythroid cells via JAK2/PI3K/Akt, demonstrating that different cell types employ different TIMP-1 receptor assemblies.","evidence":"siRNA knockdown of proMMP-9 and CD44, function-blocking antibodies, flow cytometry in UT-7 cells","pmids":["19010442"],"confidence":"High","gaps":["Whether proMMP-9/CD44 and CD63 complexes coexist on the same cell untested","Structural basis of TIMP-1/proMMP-9 interaction at the cell surface not resolved"]},{"year":2008,"claim":"Domain-dissection showed the C-terminal domain of TIMP-1 is required for ADAM-10 inhibition—unlike MMPs which are inhibited by N-TIMP-1 alone—explaining differential domain requirements for metalloproteinase versus sheddase inhibition.","evidence":"Inhibition assays comparing full-length TIMP-1 vs N-TIMP-1 against ADAM-10, ADAM-17, and MMPs","pmids":["18215140"],"confidence":"High","gaps":["Specific C-terminal residues mediating ADAM-10 contact not identified","No co-crystal structure of TIMP-1/ADAM-10"]},{"year":2011,"claim":"Two independent studies established TIMP-1 as a paracrine regulator in specialized tissues: astrocyte-derived TIMP-1 promotes oligodendrocyte differentiation and CNS myelination (MMP-independent), while tumor-derived TIMP-1 maintains Met signaling by inhibiting ADAM-10-mediated Met shedding in metastatic foci.","evidence":"TIMP-1 KO mice and neurosphere cultures with GM6001 control (myelination); reciprocal Timp-1/Adam-10 knockdown in syngeneic liver metastasis model (Met signaling)","pmids":["21508247","21789719"],"confidence":"High","gaps":["Receptor for TIMP-1's MMP-independent trophic action on OPCs not yet identified at this time point","Whether ADAM-10 inhibition is the sole mechanism maintaining Met in metastatic cells not excluded"]},{"year":2013,"claim":"TIMP-1 was shown to control angiogenesis by determining the ratio of TIMP-1-free to TIMP-1-complexed proMMP-9: M2 macrophages downregulate TIMP-1, releasing pro-angiogenic free proMMP-9, while re-complexing with exogenous TIMP-1 abolishes angiogenic activity.","evidence":"Macrophage polarization, TIMP-1 siRNA, in vivo angiogenesis assay, Mmp9-null macrophages, proMMP-9 reconstitution","pmids":["24174628"],"confidence":"High","gaps":["Mechanism by which free proMMP-9 promotes angiogenesis not fully resolved","Relevance to tumor-associated macrophage biology in vivo not directly tested"]},{"year":2015,"claim":"Domain-dissecting TIMP-1 variants in CD63-null mice proved that the CD63-binding signaling domain alone is necessary and sufficient for TIMP-1-driven granulopoiesis and neutrophilia, establishing in vivo functional separation of protease-inhibitory and cytokine activities.","evidence":"TIMP-1 domain variants, CD63-null mice, BrdU pulse-labeling, bone marrow gene expression","pmids":["26001794"],"confidence":"High","gaps":["Precise structural interface between TIMP-1 and CD63 not mapped at residue level","Whether other TIMP-1 receptors contribute to hematopoiesis not excluded"]},{"year":2018,"claim":"The downstream signaling pathway for TIMP-1-driven oligodendrocyte differentiation was delineated as CD63/β1-integrin→Akt→β-catenin stabilization, linking TIMP-1's cytokine function to Wnt pathway crosstalk in OPCs.","evidence":"Recombinant TIMP-1 treatment of OPCs, CD63/β1-integrin blocking, Akt inhibitors, β-catenin reporter, Wnt7a co-treatment","pmids":["30121936"],"confidence":"Medium","gaps":["Single-lab finding; independent replication needed","Direct β-catenin stabilization mechanism not biochemically resolved"]},{"year":2021,"claim":"CD74 (invariant chain) was identified as a third TIMP-1 receptor: the N-terminal domain of TIMP-1 binds CD74 and triggers ZAP-70 phosphorylation, establishing a proinflammatory signaling axis distinct from the CD63 and proMMP-9/CD44 pathways.","evidence":"Unbiased ligand-receptor capture, co-immunoprecipitation, confocal microscopy, in silico docking, recombinant N-TIMP-1, blocking peptide, ZAP-70 phosphorylation","pmids":["34391782"],"confidence":"High","gaps":["Downstream transcriptional programs activated by TIMP-1/CD74/ZAP-70 not characterized","Whether CD74 and CD63 compete for TIMP-1 binding unclear"]},{"year":2023,"claim":"APP and APLP2 were identified as a fourth TIMP-1 receptor pair—mediated by TIMP-1's C-terminal domain—through which TIMP-1 drives glucose uptake and proinflammatory cytokine expression in monocytes, revealing yet another signaling axis.","evidence":"Unbiased ligand-receptor capture, pull-down assays, confocal microscopy, C-terminal domain variants, glucose uptake and cytokine assays","pmids":["36629908"],"confidence":"High","gaps":["Signaling intermediates between APP and glucose uptake unknown","Whether APP mediates TIMP-1 effects in neurons or other APP-expressing tissues untested"]},{"year":2023,"claim":"ADAMTS-7 was identified as a protease that directly degrades TIMP-1, derepressing MMP-9 activity and reducing collagen in atherosclerotic plaques—revealing a proteolytic mechanism that regulates TIMP-1 availability in vivo.","evidence":"Mass spectrometry of Apoe−/−Adamts7−/− vs Apoe−/− plaques, co-immunoprecipitation, in vitro degradation assays, FRET, immunofluorescence","pmids":["37675562"],"confidence":"High","gaps":["Cleavage sites on TIMP-1 not precisely mapped","Whether other ADAMTS family members also degrade TIMP-1 untested"]},{"year":null,"claim":"Key open questions include: how TIMP-1 simultaneously engages multiple receptor complexes (CD63, proMMP-9/CD44, CD74, APP/APLP2) with apparently different domain surfaces; the atomic-resolution structure of TIMP-1/CD63 and TIMP-1/CD74 complexes; and the in vivo hierarchy and tissue specificity among these signaling axes.","evidence":"","pmids":[],"confidence":"High","gaps":["No co-crystal structure of TIMP-1 with any of its cytokine receptors","Relative contributions of each receptor pathway in specific tissues or disease contexts largely unknown","Intracellular TIMP-1 functions, if any, remain uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,3,4,5,6,9,32]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[7,10,11,17,18,23,24]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,14,25,32]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[14,25]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[9,14,25,32]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,10,11,17,18,21,23,24,29]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[9,10,12]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[23,24]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[16,20]}],"complexes":[],"partners":["MMP3","MMP9","ADAM10","CD63","ITGB1","CD44","CD74","APP"],"other_free_text":[]},"mechanistic_narrative":"TIMP-1 is a secreted, disulfide-rich glycoprotein that functions both as a broad-spectrum inhibitor of matrix metalloproteinases (MMPs) and ADAM-10, and as a multifunctional cytokine that signals through several cell-surface receptor complexes to regulate cell survival, proliferation, differentiation, and migration. Its N-terminal wedge inserts into the MMP active-site cleft with Cys1 bidentately coordinating the catalytic zinc, achieving sub-nanomolar inhibition via a two-step slow tight-binding mechanism; inhibition of ADAM-10 uniquely requires the C-terminal domain [PMID:9288970, PMID:8798626, PMID:18215140]. Independent of MMP inhibition, TIMP-1 engages CD63/β1-integrin to activate FAK, PI3K/Akt, and ERK survival signaling, binds a proMMP-9/CD44 ternary complex on erythroid cells to trigger JAK2/PI3K/Akt, signals through CD74 to activate ZAP-70 in monocytes, and interacts with APP/APLP2 to drive monocyte glucose uptake and proinflammatory cytokine expression [PMID:16917503, PMID:19010442, PMID:34391782, PMID:36629908]. In vivo, TIMP-1 controls HGF bioavailability during liver regeneration, promotes oligodendrocyte differentiation in the CNS, drives granulopoiesis via CD63, and modulates angiogenesis by regulating the ratio of free to complexed proMMP-9 [PMID:15726641, PMID:21508247, PMID:26001794, PMID:24174628]."},"prefetch_data":{"uniprot":{"accession":"P01033","full_name":"Metalloproteinase inhibitor 1","aliases":["Erythroid-potentiating activity","EPA","Fibroblast collagenase inhibitor","Collagenase inhibitor","Tissue inhibitor of metalloproteinases 1","TIMP-1"],"length_aa":207,"mass_kda":23.2,"function":"Metalloproteinase inhibitor that functions by forming one to one complexes with target metalloproteinases, such as collagenases, and irreversibly inactivates them by binding to their catalytic zinc cofactor. Acts on MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP10, MMP11, MMP12, MMP13 and MMP16. Does not act on MMP14. Also functions as a growth factor that regulates cell differentiation, migration and cell death and activates cellular signaling cascades via CD63 and ITGB1. Plays a role in integrin signaling. Mediates erythropoiesis in vitro; but, unlike IL3, it is species-specific, stimulating the growth and differentiation of only human and murine erythroid progenitors","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P01033/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TIMP1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TIMP1","total_profiled":1310},"omim":[{"mim_id":"607948","title":"MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/607948"},{"mim_id":"606542","title":"HISTONE DEACETYLASE 7A; HDAC7A","url":"https://www.omim.org/entry/606542"},{"mim_id":"605441","title":"ADIPOCYTE-, C1q-, AND COLLAGEN DOMAIN-CONTAINING; ADIPOQ","url":"https://www.omim.org/entry/605441"},{"mim_id":"603308","title":"CATHEPSIN V; CTSV","url":"https://www.omim.org/entry/603308"},{"mim_id":"603030","title":"TOLL-LIKE RECEPTOR 4; TLR4","url":"https://www.omim.org/entry/603030"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"},{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"blood vessel","ntpm":2942.8}],"url":"https://www.proteinatlas.org/search/TIMP1"},"hgnc":{"alias_symbol":["EPO"],"prev_symbol":["TIMP","CLGI"]},"alphafold":{"accession":"P01033","domains":[{"cath_id":"2.40.50.120","chopping":"30-200","consensus_level":"medium","plddt":93.5019,"start":30,"end":200}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P01033","model_url":"https://alphafold.ebi.ac.uk/files/AF-P01033-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P01033-F1-predicted_aligned_error_v6.png","plddt_mean":89.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TIMP1","jax_strain_url":"https://www.jax.org/strain/search?query=TIMP1"},"sequence":{"accession":"P01033","fasta_url":"https://rest.uniprot.org/uniprotkb/P01033.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P01033/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P01033"}},"corpus_meta":[{"pmid":"10956632","id":"PMC_10956632","title":"TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment?","date":"2000","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10956632","citation_count":338,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10818225","id":"PMC_10818225","title":"The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3.","date":"2000","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10818225","citation_count":334,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23982756","id":"PMC_23982756","title":"Cytokine functions of TIMP-1.","date":"2013","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/23982756","citation_count":246,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9036981","id":"PMC_9036981","title":"Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9036981","citation_count":171,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20507371","id":"PMC_20507371","title":"Salivary MMP-8, TIMP-1, and ICTP as markers of advanced periodontitis.","date":"2010","source":"Journal of clinical periodontology","url":"https://pubmed.ncbi.nlm.nih.gov/20507371","citation_count":153,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15333786","id":"PMC_15333786","title":"EGF-induced trophoblast secretion of MMP-9 and TIMP-1 involves activation of both PI3K and MAPK signalling pathways.","date":"2004","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15333786","citation_count":137,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30243515","id":"PMC_30243515","title":"Recognizing the Molecular Multifunctionality and Interactome of TIMP-1.","date":"2018","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/30243515","citation_count":130,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25887776","id":"PMC_25887776","title":"Emerging EPO and EPO receptor regulators and signal transducers.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25887776","citation_count":130,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15726641","id":"PMC_15726641","title":"Metalloproteinase inhibitor TIMP-1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration.","date":"2005","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/15726641","citation_count":120,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24143225","id":"PMC_24143225","title":"TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24143225","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21508247","id":"PMC_21508247","title":"Astrocytic tissue inhibitor of metalloproteinase-1 (TIMP-1) promotes oligodendrocyte differentiation and enhances CNS myelination.","date":"2011","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/21508247","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17569872","id":"PMC_17569872","title":"Role of TIMP-1 and TIMP-2 in the progression of cerebral aneurysms.","date":"2007","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/17569872","citation_count":99,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19469687","id":"PMC_19469687","title":"Neuroprotective effects of overexpressing tissue inhibitor of metalloproteinase TIMP-1.","date":"2009","source":"Journal of neurotrauma","url":"https://pubmed.ncbi.nlm.nih.gov/19469687","citation_count":97,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8906876","id":"PMC_8906876","title":"Tyrosine phosphorylation is crucial for growth signaling by tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2).","date":"1996","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/8906876","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15530852","id":"PMC_15530852","title":"TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms.","date":"2004","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15530852","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11792150","id":"PMC_11792150","title":"TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis.","date":"2002","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/11792150","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16896312","id":"PMC_16896312","title":"MMP-12, MMP-3, and TIMP-1 are markedly upregulated in chronic demyelinating theiler murine encephalomyelitis.","date":"2006","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16896312","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36163148","id":"PMC_36163148","title":"Cut loose TIMP-1: an emerging cytokine in inflammation.","date":"2022","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/36163148","citation_count":78,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12147614","id":"PMC_12147614","title":"Modulation of matrix metalloproteinase and TIMP-1 expression by cytokines in human RPE cells.","date":"2002","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/12147614","citation_count":78,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1629188","id":"PMC_1629188","title":"Identification of TIMP-2 in human alveolar macrophages. Regulation of biosynthesis is opposite to that of metalloproteinases and TIMP-1.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1629188","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12032189","id":"PMC_12032189","title":"Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease.","date":"2002","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/12032189","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15781325","id":"PMC_15781325","title":"Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression.","date":"2005","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/15781325","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8912720","id":"PMC_8912720","title":"Endogenous TGF-beta activity is modified during cellular aging: effects on metalloproteinase and TIMP-1 expression.","date":"1996","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/8912720","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12506073","id":"PMC_12506073","title":"Effects of Th2 cytokines on expression of collagen, MMP-1, and TIMP-1 in conjunctival fibroblasts.","date":"2003","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/12506073","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12147251","id":"PMC_12147251","title":"Both tissue inhibitors of metalloproteinases-1 (TIMP-1) and TIMP-2 activate Ras but through different pathways.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12147251","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21903858","id":"PMC_21903858","title":"BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.","date":"2011","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21903858","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19524176","id":"PMC_19524176","title":"Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment.","date":"2008","source":"European journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19524176","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17047657","id":"PMC_17047657","title":"TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis.","date":"2006","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17047657","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21641958","id":"PMC_21641958","title":"Localization of MMP-2, MMP-9, TIMP-1, and TIMP-2 in human coronal dentine.","date":"2011","source":"Journal of dentistry","url":"https://pubmed.ncbi.nlm.nih.gov/21641958","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8485170","id":"PMC_8485170","title":"Inhibition of stimulated bone resorption in vitro by TIMP-1 and TIMP-2.","date":"1993","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/8485170","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8608981","id":"PMC_8608981","title":"Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer.","date":"1996","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8608981","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7562346","id":"PMC_7562346","title":"Growth factor effects on the expression of collagenase and TIMP-1 in periodontal ligament cells.","date":"1995","source":"Journal of periodontology","url":"https://pubmed.ncbi.nlm.nih.gov/7562346","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10524225","id":"PMC_10524225","title":"Induction of TIMP-1 expression in rat hepatic stellate cells and hepatocytes: a new role for homocysteine in liver fibrosis.","date":"1999","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/10524225","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26549110","id":"PMC_26549110","title":"TIMP-1 mediates TGF-β-dependent crosstalk between hepatic stellate and cancer cells via FAK signaling.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26549110","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25137018","id":"PMC_25137018","title":"Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies.","date":"2014","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25137018","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22957045","id":"PMC_22957045","title":"Nitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22957045","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20207965","id":"PMC_20207965","title":"Effect of TIMP-1 and MMP in pterygium invasion.","date":"2010","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/20207965","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9357863","id":"PMC_9357863","title":"Divergent regulation of 92-kDa gelatinase and TIMP-1 by HBECs in response to IL-1beta and TNF-alpha.","date":"1997","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9357863","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17716308","id":"PMC_17716308","title":"MMP-13 and TIMP-1 determinations in progressive chronic periodontitis.","date":"2007","source":"Journal of clinical periodontology","url":"https://pubmed.ncbi.nlm.nih.gov/17716308","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15105792","id":"PMC_15105792","title":"Elements of the nitric oxide pathway can degrade TIMP-1 and increase gelatinase activity.","date":"2004","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/15105792","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28386095","id":"PMC_28386095","title":"TIMP-1 is upregulated, but not essential in hepatic fibrogenesis and carcinogenesis in mice.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28386095","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10408860","id":"PMC_10408860","title":"'Proteolytic switching': opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression.","date":"1999","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10408860","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26001794","id":"PMC_26001794","title":"TIMP-1 signaling via CD63 triggers granulopoiesis and neutrophilia in mice.","date":"2015","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/26001794","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21789719","id":"PMC_21789719","title":"Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10.","date":"2011","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/21789719","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24635319","id":"PMC_24635319","title":"TIMP-1 modulates chemotaxis of human neural stem cells through CD63 and integrin signalling.","date":"2014","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/24635319","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22285381","id":"PMC_22285381","title":"Evaluation of plasmatic MMP-8, MMP-9, TIMP-1 and MPO levels in obese and lean women.","date":"2012","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22285381","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10232461","id":"PMC_10232461","title":"Timp-1, -2 and -3 show coexpression with gelatinases A and B during mouse tooth morphogenesis.","date":"1999","source":"European journal of oral sciences","url":"https://pubmed.ncbi.nlm.nih.gov/10232461","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20683677","id":"PMC_20683677","title":"Leptin regulates MMP-2, TIMP-1 and collagen synthesis via p38 MAPK in HL-1 murine cardiomyocytes.","date":"2010","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/20683677","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19010442","id":"PMC_19010442","title":"TIMP-1 binding to proMMP-9/CD44 complex localized at the cell surface promotes erythroid cell survival.","date":"2008","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19010442","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37675562","id":"PMC_37675562","title":"ADAMTS-7 Modulates Atherosclerotic Plaque Formation by Degradation of TIMP-1.","date":"2023","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/37675562","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23834019","id":"PMC_23834019","title":"Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review.","date":"2013","source":"Scandinavian journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/23834019","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30121936","id":"PMC_30121936","title":"TIMP-1 Promotes Oligodendrocyte Differentiation Through Receptor-Mediated Signaling.","date":"2018","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/30121936","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11369004","id":"PMC_11369004","title":"Oxidized LDL differentially regulates MMP-1 and TIMP-1 expression in vascular endothelial cells.","date":"2001","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/11369004","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22407827","id":"PMC_22407827","title":"TIMP-1 deficiency leads to lethal partial hepatic ischemia and reperfusion injury.","date":"2012","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/22407827","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23953287","id":"PMC_23953287","title":"MMP-7 and TIMP-1, new targets in predicting poor wound healing in apical periodontitis.","date":"2013","source":"Journal of endodontics","url":"https://pubmed.ncbi.nlm.nih.gov/23953287","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25756591","id":"PMC_25756591","title":"TIMP-1 overexpression in lung carcinoma enhances tumor kinetics and angiogenesis in brain metastasis.","date":"2015","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25756591","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20205165","id":"PMC_20205165","title":"Angiogenesis in vestibular schwannomas: expression of extracellular matrix factors MMP-2, MMP-9, and TIMP-1.","date":"2010","source":"The Laryngoscope","url":"https://pubmed.ncbi.nlm.nih.gov/20205165","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9657677","id":"PMC_9657677","title":"TIMP-1 contact sites and perturbations of stromelysin 1 mapped by NMR and a paramagnetic surface probe.","date":"1998","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9657677","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22718114","id":"PMC_22718114","title":"The endogenous protease inhibitor TIMP-1 mediates protection and recovery from cutaneous photodamage.","date":"2012","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/22718114","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23909892","id":"PMC_23909892","title":"TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells.","date":"2013","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/23909892","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16718785","id":"PMC_16718785","title":"Correlation between TIMP-1 expression and liver fibrosis in two rat liver fibrosis models.","date":"2006","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/16718785","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8798626","id":"PMC_8798626","title":"The mechanism of inhibition of collagenase by TIMP-1.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8798626","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18215140","id":"PMC_18215140","title":"The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.","date":"2008","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/18215140","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20578063","id":"PMC_20578063","title":"Epidermal growth factor (EGF) induces motility and upregulates MMP-9 and TIMP-1 in bovine trophoblast cells.","date":"2010","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/20578063","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26419263","id":"PMC_26419263","title":"Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.","date":"2015","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/26419263","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11032844","id":"PMC_11032844","title":"The human tissue inhibitor of metalloproteinases (TIMP)-1 gene contains repressive elements within the promoter and intron 1.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11032844","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32961536","id":"PMC_32961536","title":"The Behavior of MMP-2, MMP-7, MMP-9, and Their Inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer Sequence.","date":"2020","source":"Digestive diseases (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32961536","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7507419","id":"PMC_7507419","title":"Characterization of a human corneal metalloproteinase inhibitor (TIMP-1).","date":"1993","source":"Current eye research","url":"https://pubmed.ncbi.nlm.nih.gov/7507419","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25009588","id":"PMC_25009588","title":"Effect of osteopontin on TIMP-1 and TIMP-2 mRNA in chondrocytes of human knee osteoarthritis in vitro.","date":"2014","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25009588","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33942633","id":"PMC_33942633","title":"Diagnostic values of MMP-7, MMP-9, MMP-11, TIMP-1, TIMP-2, CEA, and CA19-9 in patients with colorectal cancer.","date":"2021","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/33942633","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30473539","id":"PMC_30473539","title":"TIMP-1 inhibits proliferation and osteogenic differentiation of hBMSCs through Wnt/β-catenin signaling.","date":"2019","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/30473539","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36629908","id":"PMC_36629908","title":"TIMP-1 is a novel ligand of Amyloid Precursor Protein and triggers a proinflammatory phenotype in human monocytes.","date":"2023","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/36629908","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29845213","id":"PMC_29845213","title":"Involvement of TIMP-1 in PECAM-1-mediated tumor dissemination.","date":"2018","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29845213","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30507031","id":"PMC_30507031","title":"Genetic variants of erythropoietin (EPO) and EPO receptor genes in familial erythrocytosis.","date":"2018","source":"International journal of laboratory hematology","url":"https://pubmed.ncbi.nlm.nih.gov/30507031","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30557571","id":"PMC_30557571","title":"Corneal regeneration by conditioned medium of human uterine cervical stem cells is mediated by TIMP-1 and TIMP-2.","date":"2018","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/30557571","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16288749","id":"PMC_16288749","title":"Proinflammatory adipocytokines induce TIMP-1 expression in 3T3-L1 adipocytes.","date":"2005","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/16288749","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10098765","id":"PMC_10098765","title":"Tissue inhibitor of metalloproteinases-1 (TIMP-1) mRNA is elevated in advanced stages of thyroid carcinoma.","date":"1999","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10098765","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14523226","id":"PMC_14523226","title":"Serum MMP-1 and TIMP-1 levels are increased in patients with psoriatic arthritis and their siblings.","date":"2003","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/14523226","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18391843","id":"PMC_18391843","title":"Bronchoalveolar lavage MMP-9 and TIMP-1 in preschool wheezers and their relationship to persistent wheeze.","date":"2008","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/18391843","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16261161","id":"PMC_16261161","title":"GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16261161","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21080973","id":"PMC_21080973","title":"Upregulation of MMP-13 and TIMP-1 expression in response to mechanical strain in MC3T3-E1 osteoblastic cells.","date":"2010","source":"BMC research notes","url":"https://pubmed.ncbi.nlm.nih.gov/21080973","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34557330","id":"PMC_34557330","title":"The role of matrix metalloproteinase-9 and its inhibitor TIMP-1 in burn injury: a systematic review.","date":"2021","source":"International journal of burns and trauma","url":"https://pubmed.ncbi.nlm.nih.gov/34557330","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30486830","id":"PMC_30486830","title":"Inhibition of skin carcinogenesis by suppression of NF-κB dependent ITGAV and TIMP-1 expression in IL-32γ overexpressed condition.","date":"2018","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30486830","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28451395","id":"PMC_28451395","title":"Association of COL4A3 (rs55703767), MMP-9 (rs17576)and TIMP-1 (rs6609533) gene polymorphisms with susceptibility to type 2 diabetes.","date":"2017","source":"Biomedical reports","url":"https://pubmed.ncbi.nlm.nih.gov/28451395","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30035371","id":"PMC_30035371","title":"TFF1 antagonizes TIMP-1 mediated proliferative functions in gastric cancer.","date":"2018","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/30035371","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31861382","id":"PMC_31861382","title":"TIMP-1 is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31861382","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28197741","id":"PMC_28197741","title":"Correlation between the COL4A3, MMP-9, and TIMP-1 polymorphisms and risk of keratoconus.","date":"2017","source":"Japanese journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/28197741","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11918744","id":"PMC_11918744","title":"STAT1 and STAT3 mediate thrombin-induced expression of TIMP-1 in human glomerular mesangial cells.","date":"2002","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/11918744","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34391782","id":"PMC_34391782","title":"Identification of invariant chain CD74 as a functional receptor of tissue inhibitor of metalloproteinases-1 (TIMP-1).","date":"2021","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34391782","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19780057","id":"PMC_19780057","title":"Bone loss induced by Runx2 over-expression in mice is blunted by osteoblastic over-expression of TIMP-1.","date":"2010","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19780057","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19043814","id":"PMC_19043814","title":"The role of MMP-9 and TIMP-1 in nasal polyp formation.","date":"2008","source":"Swiss medical weekly","url":"https://pubmed.ncbi.nlm.nih.gov/19043814","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23175213","id":"PMC_23175213","title":"Gambogic acid inhibits invasion of osteosarcoma via upregulation of TIMP-1.","date":"2012","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23175213","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8808115","id":"PMC_8808115","title":"Glomerular expression of tissue inhibitor of metalloproteinase (TIMP-1) in normal and diabetic rats.","date":"1996","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/8808115","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28775117","id":"PMC_28775117","title":"Endotoxemia shifts neutrophils with TIMP-free gelatinase B/MMP-9 from bone marrow to the periphery and induces systematic upregulation of TIMP-1.","date":"2017","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/28775117","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31258700","id":"PMC_31258700","title":"MMP-9 and TIMP-1 in placenta of hypertensive disorder complicating pregnancy.","date":"2019","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31258700","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35625637","id":"PMC_35625637","title":"Increase in Serum MMP-9 and TIMP-1 Concentrations during Alcohol Intoxication in Adolescents-A Preliminary Study.","date":"2022","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/35625637","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29938527","id":"PMC_29938527","title":"Effects of Controlling Abnormal Joint Movement on Expression of MMP13 and TIMP-1 in Osteoarthritis.","date":"2018","source":"Cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/29938527","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25693084","id":"PMC_25693084","title":"Diagnostic significance of TIMP-1 level in serum and its immunohistochemical expression in colorectal cancer patients.","date":"2014","source":"Polish journal of pathology : official journal of the Polish Society of Pathologists","url":"https://pubmed.ncbi.nlm.nih.gov/25693084","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10575588","id":"PMC_10575588","title":"Tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) stimulate osteoclastic bone resorption.","date":"1999","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10575588","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23943285","id":"PMC_23943285","title":"Identification of miR-1293 potential target gene: TIMP-1.","date":"2013","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23943285","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33419373","id":"PMC_33419373","title":"The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33419373","citation_count":1233,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3903517","id":"PMC_3903517","title":"Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity.","date":"1985","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/3903517","citation_count":671,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14630798","id":"PMC_14630798","title":"Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14630798","citation_count":616,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12714508","id":"PMC_12714508","title":"The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12714508","citation_count":603,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9288970","id":"PMC_9288970","title":"Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9288970","citation_count":499,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11796725","id":"PMC_11796725","title":"Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11796725","citation_count":360,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16335952","id":"PMC_16335952","title":"Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.","date":"2005","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/16335952","citation_count":350,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3010309","id":"PMC_3010309","title":"Primary structure and cDNA cloning of human fibroblast collagenase inhibitor.","date":"1986","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3010309","citation_count":306,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8804434","id":"PMC_8804434","title":"Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2.","date":"1996","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/8804434","citation_count":294,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16917503","id":"PMC_16917503","title":"Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein.","date":"2006","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/16917503","citation_count":277,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3839290","id":"PMC_3839290","title":"Molecular characterization and expression of the gene encoding human erythroid-potentiating activity.","date":"1985","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/3839290","citation_count":271,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"36369321","id":"PMC_36369321","title":"CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stability via OTUB1.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/36369321","citation_count":259,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16103240","id":"PMC_16103240","title":"Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart.","date":"2005","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/16103240","citation_count":258,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27644693","id":"PMC_27644693","title":"TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway.","date":"2016","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/27644693","citation_count":235,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24174628","id":"PMC_24174628","title":"Angiogenic capacity of M1- and M2-polarized macrophages is determined by the levels of TIMP-1 complexed with their secreted proMMP-9.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24174628","citation_count":206,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11279011","id":"PMC_11279011","title":"The low density lipoprotein receptor-related protein modulates levels of matrix metalloproteinase 9 (MMP-9) by mediating its cellular catabolism.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11279011","citation_count":182,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2163605","id":"PMC_2163605","title":"Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP).","date":"1990","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/2163605","citation_count":176,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16740002","id":"PMC_16740002","title":"Identification of N-linked glycoproteins in human saliva by glycoprotein capture and mass spectrometry.","date":"2006","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/16740002","citation_count":173,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18159069","id":"PMC_18159069","title":"Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1.","date":"2007","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/18159069","citation_count":171,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25263437","id":"PMC_25263437","title":"Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25263437","citation_count":165,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12651627","id":"PMC_12651627","title":"Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease.","date":"2003","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12651627","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19913121","id":"PMC_19913121","title":"Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19913121","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12904305","id":"PMC_12904305","title":"Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12904305","citation_count":159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14648584","id":"PMC_14648584","title":"Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system.","date":"2003","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/14648584","citation_count":159,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51701,"output_tokens":7332,"usd":0.132542},"stage2":{"model":"claude-opus-4-6","input_tokens":11084,"output_tokens":5000,"usd":0.27063},"total_usd":0.867131,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":66331,"output_tokens":10217,"usd":0.176124},"round2_rules_fired":"R2,R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":14463,"output_tokens":4783,"usd":0.287835}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"TIMP-1 (and TIMP-3) inhibits the catalytic activity of ADAM-10 with an apparent inhibition constant of ~0.1 nM, whereas TIMP-2 and TIMP-4 cannot inhibit ADAM-10. This distinguishes TIMP-1's inhibitory profile from TACE, which is only inhibited by TIMP-3.\",\n      \"method\": \"In vitro enzymatic assay using quenched fluorescent substrate and myelin basic protein degradation assay with recombinant soluble ADAM-10 catalytic domain\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstituted enzymatic inhibition assay with quantified Ki constants\",\n      \"pmids\": [\"10818225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"TIMP-1-stimulated cell growth signaling requires tyrosine kinase activity and involves activation of MAP kinase, as tyrosine kinase inhibitors (genistein, erbstatin, herbimycin A) abolish TIMP-1-induced [3H]thymidine incorporation and TIMP-1 elevates phosphotyrosine-containing proteins and MAP kinase activity in MG-63 osteosarcoma cells.\",\n      \"method\": \"Radioactive thymidine incorporation assay, kinase inhibitor experiments, MAP kinase activity assay in human osteosarcoma cells\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean pharmacological dissection with multiple inhibitors and kinase activity readout, single lab\",\n      \"pmids\": [\"8906876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TIMP-1 activates Ras (increases Ras-GTP levels) through a tyrosine kinase (TYK)/MAPK-dependent pathway (inhibited by herbimycin A), distinct from the PKA-dependent pathway used by TIMP-2 to activate Ras, in MG-63 human osteosarcoma cells.\",\n      \"method\": \"Ras-GTP pull-down assay, pharmacological inhibitors (herbimycin A, H89) in MG-63 cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct Ras-GTP measurement with pathway-specific inhibitors, single lab\",\n      \"pmids\": [\"12147251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"TIMP-1 inhibits fibroblast-type collagenase (MMP-1) by a noncompetitive two-step slow tight-binding mechanism: a rapidly formed reversible complex (Kd ~8 nM) slowly isomerizes to a tight complex (global Kd ~0.1 nM). The C-terminal domain of collagenase is required for initial rapid TIMP-1 binding and lowers the overall Kd.\",\n      \"method\": \"In vitro kinetic analysis by graphical analysis, nonlinear regression, and numeric integration of time-course inhibition data using recombinant proteins including C-terminal-truncated mini-collagenase\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — rigorous in vitro kinetic analysis with multiple analytical approaches and domain-deletion variant\",\n      \"pmids\": [\"8798626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The N-terminal inhibitory domain of TIMP-1 (N-TIMP-1) contacts residues Tyr155, Asn162, Val163, Leu164, His166, Ala167, Ala169, and Phe210 of MMP-3 at the binding interface, displaces the N-terminus of MMP-3, and induces conformational changes near the MMP-3 active site, as mapped by NMR and paramagnetic surface probing.\",\n      \"method\": \"NMR spectroscopy with paramagnetic Gd-EDTA surface probe and amide hydrogen exchange in solution, validated against X-ray crystal structure\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR-based structural mapping with paramagnetic probe; consistent with crystal structure\",\n      \"pmids\": [\"9657677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TIMP-1 negatively regulates hepatocyte cell cycle progression during liver regeneration by limiting HGF bioavailability; TIMP-1 loss of function (knockout mice) accelerates hepatocyte entry into G1-S, S, and M phases and increases active HGF levels and phosphorylated Met signaling, while TIMP-1 gain of function delays cell cycle progression.\",\n      \"method\": \"TIMP-1 knockout and transgenic overexpression mouse models, cyclin D1/PCNA/phospho-histone H3 immunostaining, MMP activity assay, HGF/phospho-Met immunostaining\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal loss- and gain-of-function genetic models with multiple cell-cycle markers and defined pathway readout\",\n      \"pmids\": [\"15726641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"TIMP-1 inhibits microvascular endothelial cell migration through two distinct mechanisms: (1) MMP-dependent upregulation of junctional proteins VE-cadherin and PECAM-1; and (2) MMP-independent stimulation of PTEN expression with subsequent dephosphorylation of focal adhesion kinase (FAK, pY397) and paxillin, and reduction of F-actin stress fibers and focal adhesions.\",\n      \"method\": \"In vitro cell migration assay with recombinant TIMP-1 and synthetic MMP inhibitors, Western blotting for VE-cadherin, PECAM-1, PTEN, phospho-FAK, and paxillin in HDMVEC\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection of MMP-dependent vs. independent pathways with protein-level mechanistic readouts, single lab\",\n      \"pmids\": [\"15530852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TIMP-1 promotes erythroid cell survival (anti-apoptotic signaling via JAK2/PI3K/Akt) by binding to proMMP-9 associated with the cell surface; CD44 anchors proMMP-9 to the plasma membrane forming a ternary TIMP-1/proMMP-9/CD44 complex required for signal transduction, independently of MMP enzymatic activity.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown of proMMP-9 and CD44, MMP function-blocking antibodies, synthetic MMP inhibitor controls in UT-7 erythroid cells\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding demonstrated by Co-IP, with genetic and pharmacological controls dissecting MMP-independent signaling mechanism\",\n      \"pmids\": [\"19010442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Tumor cell-derived TIMP-1 maintains Met (HGF receptor) signaling by inhibiting the Met sheddase ADAM-10; knockdown of tumor cell TIMP-1 suppresses Met phosphorylation in metastases and inhibits liver metastasis formation, while ADAM-10 knockdown phenocopies TIMP-1 by triggering Met auto-phosphorylation.\",\n      \"method\": \"Syngeneic mouse experimental liver metastasis model, siRNA knockdown of Timp-1 and Adam-10, immunostaining for phospho-Met in metastatic foci, in vitro HGF-stimulated Met phosphorylation assay\",\n      \"journal\": \"Clinical & experimental metastasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo and in vitro with reciprocal knockdowns establishing TIMP-1→ADAM-10→Met signaling axis\",\n      \"pmids\": [\"21789719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TIMP-1 signals through CD63 to induce granulopoiesis and neutrophilia in mice; the C-terminal signaling domain of TIMP-1 (not its protease-inhibitory N-terminal domain) is necessary and sufficient for this effect, and ablation of CD63 abolishes TIMP-1-induced neutrophilia and bone marrow granulopoiesis.\",\n      \"method\": \"Systemic TIMP-1 administration in mice, TIMP-1 domain-dissection variants, CD63-knockout mice, BrdU pulse-labeling of proliferating progenitors, granulopoiesis gene expression analysis\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — domain-function dissection with genetic receptor knockout and in vivo BrdU labeling; multiple orthogonal approaches\",\n      \"pmids\": [\"26001794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Astrocyte-secreted TIMP-1 promotes oligodendrocyte progenitor cell (OPC) differentiation and CNS myelination through a mechanism independent of MMP inhibition, as recombinant TIMP-1 but not the broad MMP inhibitor GM6001 rescued OPC differentiation deficits in TIMP-1 knockout neurosphere cultures.\",\n      \"method\": \"TIMP-1 knockout mice, recombinant TIMP-1 rescue experiments in neurosphere cultures, immunopanned OPC cultures, conditioned media experiments, GM6001 controls\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with pharmacological controls discriminating MMP-independent trophic activity; multiple cell culture readouts\",\n      \"pmids\": [\"21508247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TIMP-1 signals through CD63 in complex with β1-integrin to activate Akt and promote β-catenin signaling, driving oligodendrocyte progenitor cell differentiation; this trophic activity resides in the C-terminal domain of TIMP-1 and is counteracted but not abrogated by Wnt7a canonical signaling.\",\n      \"method\": \"CD63/β1-integrin blocking antibodies, pharmacological PI3K inhibition, Western blotting for Akt/β-catenin in OPCs, recombinant TIMP-1 treatment\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor blocking and pathway inhibition with defined signaling readouts, single lab\",\n      \"pmids\": [\"30121936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TIMP-1 binding to CD63 activates Akt signaling through the PI3K pathway, conferring anti-apoptotic activity in papillary thyroid carcinoma cells; this loop is initiated downstream of BRAF(V600E) via NF-κB-mediated TIMP-1 upregulation.\",\n      \"method\": \"BRAF gene silencing by siRNA in BCPAP cells, MAPK pathway inhibitors, immunoprecipitation of TIMP-1/CD63, measurement of Akt phosphorylation, invasion assays\",\n      \"journal\": \"Endocrine-related cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA knockdown + pharmacological inhibition + Co-IP defining the BRAF→NF-κB→TIMP-1→CD63→Akt axis, single lab\",\n      \"pmids\": [\"21903858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TIMP-1 mediates TGF-β-dependent crosstalk between hepatic stellate cells and hepatocellular carcinoma cells via CD63-dependent activation of focal adhesion kinase (FAK) signaling, promoting HCC cell proliferation, motility, and survival.\",\n      \"method\": \"Co-culture systems, TGF-β receptor kinase inhibitor EW-7197, TIMP-1 secretion measurement, FAK phosphorylation assays, orthotopic xenograft mouse model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — inhibitor-based pathway dissection with in vivo validation, single lab\",\n      \"pmids\": [\"26549110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TIMP-1 modulates human neural stem cell chemotaxis and adhesion by binding to CD63, which activates β1-integrin-mediated signaling through Akt and FAK phosphorylation, leading to cytoskeletal reorganization; shRNA knockdown of CD63 or blocking β1-integrin or PI3K abrogates TIMP-1-induced migration.\",\n      \"method\": \"Microarray and proteomics identification, shRNA knockdown of CD63, β1-integrin blocking antibody, PI3K inhibitor, focal adhesion counting, F-actin visualization in hNSCs\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor knockdown plus multiple pharmacological controls with defined cytoskeletal readouts, single lab\",\n      \"pmids\": [\"24635319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CD74 (invariant chain) is a functional receptor for TIMP-1; TIMP-1 binds CD74 via its N-terminal domain, and this interaction triggers intracellular ZAP-70 activation in B lymphoma cells. The N-terminal domain of TIMP-1 alone is sufficient for CD74 binding and ZAP-70 activation, and blocking CD74's cytokine-binding site abrogates TIMP-1-mediated ZAP-70 signaling.\",\n      \"method\": \"Ligand-receptor capture screening, co-immunoprecipitation, confocal microscopy, in silico HADDOCK docking, dot blot binding assay, recombinant N-TIMP-1 domain, synthetic blocking peptide, ZAP-70 phosphorylation assay in Namalwa cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — unbiased receptor identification confirmed by multiple orthogonal methods including Co-IP, confocal microscopy, domain mapping, docking, and functional signaling readout\",\n      \"pmids\": [\"34391782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TIMP-1 interacts with Amyloid Precursor Protein (APP) and APLP2 at the cell surface of human monocytes, triggering glucose uptake and proinflammatory cytokine expression via the C-terminal domain of TIMP-1; in silico docking and recombinant TIMP-1 domain variants confirmed that the C-terminal domain mediates APP binding and monocyte activation.\",\n      \"method\": \"Unbiased ligand-receptor-capture screening, pull-down assays, confocal microscopy, recombinant TIMP-1 domain variants (N-terminal vs. C-terminal), in silico docking, glucose uptake assay, cytokine expression in primary human monocytes\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — unbiased receptor identification with multiple orthogonal validation methods, domain mapping, and functional readouts\",\n      \"pmids\": [\"36629908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ADAMTS-7 degrades TIMP-1 by direct binding via its catalytic domain, reducing TIMP-1's inhibitory capacity against MMP-9 and leading to increased collagen degradation in atherosclerotic plaques; ADAMTS-7 deficiency in mice results in higher TIMP-1 levels and greater collagen content in plaques.\",\n      \"method\": \"Mass spectrometry of atherosclerotic plaques from Apoe-/- and Apoe-/-Adamts7-/- mice, co-immunoprecipitation, in vitro degradation assay, FRET-based protein interaction assay, immunofluorescence, picrosirius red staining\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro degradation assay + Co-IP + genetic mouse model + multiple validation methods demonstrating ADAMTS-7 as a TIMP-1 protease\",\n      \"pmids\": [\"37675562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Thrombin induces TIMP-1 gene expression in human glomerular mesangial cells through STAT1 and STAT3 transcription factors; antisense oligonucleotides to STAT1 and STAT3 inhibit both STAT-DNA binding activity and thrombin-induced TIMP-1 mRNA expression.\",\n      \"method\": \"Northern blot, EMSA, supershift assay, STAT antisense oligonucleotides in cultured human mesangial cells\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — antisense knockdown with EMSA/supershift validation of STAT1/STAT3 as transcriptional mediators, single lab\",\n      \"pmids\": [\"11918744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The human TIMP-1 gene contains transcriptional repressive elements both upstream of the basal promoter (at −1718/−1458) and within intron 1 (particularly at +684/+748); the intronic repressor binds Sp1, Sp3, and an unidentified Ets-related factor.\",\n      \"method\": \"Reporter gene deletion analysis, protein binding studies (EMSA), mutational analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — deletion mapping combined with EMSA and mutagenesis identifying repressive elements and their cognate binding factors\",\n      \"pmids\": [\"11032844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Homocysteine induces TIMP-1 expression in hepatic stellate cells, hepatocytes, vascular smooth muscle cells, and HepG2 cells via its thiol group and by promoting AP-1 binding activity, which is required for TIMP-1 transcriptional induction.\",\n      \"method\": \"Gene expression analysis (mRNA and protein), AP-1 binding assay (EMSA), thiol-group dependency experiments in multiple cell types\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — thiol dependency and AP-1 EMSA providing mechanistic link, replicated across multiple cell types\",\n      \"pmids\": [\"10524225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition, unlike their inhibition of MMPs and ADAM17, indicating that full-length TIMP-1 (requiring more than just the N-terminal domain) is needed for ADAM10 inhibition.\",\n      \"method\": \"In vitro enzymatic inhibition assays with N-terminal domain constructs of TIMP-1 and TIMP-3 vs. ADAM10, ADAM17, and MMPs\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro domain-function analysis, single study\",\n      \"pmids\": [\"18215140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TIMP-1 deficiency leads to lethal hepatic ischemia-reperfusion injury associated with markedly elevated MMP-9 activity, massive leukocyte infiltration, increased caspase-3, depressed Bcl-2/Akt phosphorylation, impaired hepatocyte cell cycle progression (reduced cyclins D1/E), and elevated c-Met ectodomain shedding with reduced phospho-c-Met, identifying TIMP-1 as a regulator of hepatocyte survival and proliferation via MMP-9/c-Met signaling.\",\n      \"method\": \"TIMP-1 knockout mice, partial liver IRI model, MMP-9 activity assay, immunostaining for caspase-3, Bcl-2, phospho-Akt, BrdU incorporation, PCNA, phospho-histone H3, cyclins D1/E, phospho-Met\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with multiple mechanistic readouts identifying MMP-9/c-Met as downstream effectors of TIMP-1 hepatoprotection\",\n      \"pmids\": [\"22407827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TIMP-1 promotes cancer-associated fibroblast (CAF) proliferation and migration and activates ERK1/2 kinase signaling in prostate CAF cells; increased TIMP-1 expression stimulates CAF accumulation in prostate and colon cancer tissues in vivo.\",\n      \"method\": \"TIMP-1 overexpression in cancer cells, in vivo tumor growth assays, in vitro CAF proliferation/migration assays, ERK1/2 phosphorylation Western blot\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro gain-of-function with defined signaling readout, single lab\",\n      \"pmids\": [\"24143225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TIMP-1 promotes resistance to chemotherapy-induced apoptosis; TIMP-1 gene-deficient fibrosarcoma cells derived from mouse lung tissue show markedly increased sensitivity to chemotherapy compared to wild-type counterparts, establishing a functional anti-apoptotic role for TIMP-1.\",\n      \"method\": \"TIMP-1 gene-deficient vs. wild-type genetically matched fibrosarcoma cell lines, chemotherapy-induced apoptosis assays\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isogenic KO cell system with direct apoptosis readout, single lab\",\n      \"pmids\": [\"17047657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TIMP-1-induced pro-survival PI3K/Akt/BAD signaling in breast cancer cells is mediated via CD63 receptor interaction; TIMP-1 undergoes protein nitration by NO and co-immunoprecipitates with CD63; antisense silencing of TIMP-1 blocks NO-induced PI3K/Akt/BAD phosphorylation.\",\n      \"method\": \"Co-immunoprecipitation of TIMP-1/CD63, antisense TIMP-1 silencing, Western blot for Akt/BAD phosphorylation, immunohistochemistry in breast tumor samples\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — Co-IP plus antisense knockdown with defined signaling readout, single lab\",\n      \"pmids\": [\"22957045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TIMP-1 mRNA expression in gastric cancer cells is induced by TNF-α via NF-κB activation; inhibition of NF-κB with BAY11-7082 downregulates TIMP-1, and reconstitution of TFF1 suppresses NF-κB activity and reduces TIMP-1 expression and TIMP-1-mediated cell proliferation.\",\n      \"method\": \"Quantitative RT-PCR, NF-κB inhibitor (BAY11-7082), TFF1 reconstitution in cell lines and gastric organoids, EDU proliferation assay, immunofluorescence\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological NF-κB inhibition and TFF1 reconstitution with functional proliferation readout, single lab\",\n      \"pmids\": [\"30035371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TIMP-1 inhibits proliferation and osteogenic differentiation of human bone marrow-derived MSCs through Wnt/β-catenin signaling; TIMP-1 knockdown upregulates β-catenin and cyclin D1, while TIMP-1 overexpression attenuates Wnt3a-induced RUNX-2 and cyclin D1 expression.\",\n      \"method\": \"Stable TIMP-1 overexpression and knockdown in hBMSCs, Alizarin Red staining, ALP activity, Western blotting for β-catenin/cyclin D1/RUNX-2, Wnt activator/inhibitor experiments\",\n      \"journal\": \"Bioscience reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain/loss-of-function with pathway activator/inhibitor controls, single lab\",\n      \"pmids\": [\"30473539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"miR-1293 directly binds the 3'UTR of TIMP-1 mRNA and negatively regulates TIMP-1 protein levels; luciferase reporter assay with wild-type and mutant TIMP-1 3'UTR constructs confirmed direct miR-1293/TIMP-1 interaction, with miR-1293 inhibitor increasing TIMP-1 protein.\",\n      \"method\": \"Luciferase reporter assay with wild-type and mutant TIMP-1 3'UTR, miR-1293 inhibitor/mimic transfection, Western blot in 293T cells\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct 3'UTR luciferase reporter with mutagenesis confirmation and protein-level validation\",\n      \"pmids\": [\"23943285\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TIMP-1 is a multifunctional secreted protein that (1) inhibits MMPs and ADAM-10 (but not ADAM17) through tight-binding mechanisms requiring its N-terminal domain (with ADAM-10 additionally requiring regions beyond the N-terminal domain), (2) signals as a cytokine via cell-surface receptors CD63, CD74, and APP/APLP2 to activate downstream pathways including JAK2/PI3K/Akt, FAK, and ZAP-70, (3) regulates granulopoiesis, neural stem cell migration, oligodendrocyte differentiation, and hepatocyte proliferation largely via CD63/β1-integrin/Akt signaling independently of MMP inhibition, (4) promotes anti-apoptotic and pro-proliferative signaling in multiple cell types, and (5) is itself subject to proteolytic degradation by ADAMTS-7, transcriptional regulation by NF-κB/STAT1/STAT3/AP-1, and post-transcriptional regulation by miR-1293.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1985,\n      \"finding\": \"TIMP-1 was sequenced from its cDNA and found to be identical to erythroid-potentiating activity (EPA), a glycoprotein that irreversibly forms inactive complexes with metalloproteinases. The protein consists of 184 amino acid residues with a 23-amino acid leader peptide, two N-linked oligosaccharide sites, and six disulfide bonds.\",\n      \"method\": \"cDNA cloning, protein sequencing, expression in E. coli and transfected animal cells\",\n      \"journal\": \"Nature / Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original sequence determination with protein sequencing validation, two independent labs\",\n      \"pmids\": [\"3903517\", \"3839290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The six disulfide bonds of human TIMP-1 were assigned: Cys1-Cys70, Cys3-Cys99, Cys13-Cys124, Cys127-Cys174, Cys132-Cys137, and Cys145-Cys166, defining the structural framework of the protein.\",\n      \"method\": \"Reverse-phase HPLC of proteolytic digests, reduction, Edman sequencing, and fast-atom-bombardment mass spectrometry\",\n      \"journal\": \"The Biochemical Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct structural determination with multiple orthogonal methods\",\n      \"pmids\": [\"2163605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Crystal structure of the TIMP-1/MMP-3 (stromelysin-1) complex revealed that TIMP-1 occupies the entire active-site cleft of MMP-3 with its long edge; Cys1 bidentately coordinates the catalytic zinc of MMP-3, and the Thr2 side chain inserts into the large specificity pocket, defining the canonical wedge-shaped inhibitory mechanism.\",\n      \"method\": \"X-ray crystallography of MMP-3 catalytic domain complexed with TIMP-1\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional validation, foundational mechanistic paper\",\n      \"pmids\": [\"9288970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"TIMP-1 inhibits fibroblast collagenase (MMP-1) via a two-step noncompetitive mechanism: a rapidly formed reversible complex (Kd ~8 nM) slowly isomerizes into an extremely tight complex (global Kd ~0.1 nM). The C-terminal domain of collagenase is required for the initial rapid binding step; mini-collagenase lacking this domain forms only the simpler tight complex with lower affinity.\",\n      \"method\": \"Time-course kinetic analysis by graphic analysis, nonlinear regression of analytic integrals, and numeric integration of rate equations; comparison with truncated mini-collagenase\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — rigorous in vitro kinetic analysis with multiple analytical methods and mutagenesis-equivalent domain deletion\",\n      \"pmids\": [\"8798626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"NMR and paramagnetic surface probing mapped the TIMP-1/MMP-3 interface in solution: TIMP-1 protects MMP-3 residues Tyr155, Asn162, Val163, Leu164, His166, Ala167, Ala169, and Phe210 from Gd-EDTA broadening, consistent with the crystal structure. N-TIMP-1 binding also induces conformational changes in MMP-3 helix C (Asp238, Asn240, Gly241, Ser244) and alters hydrogen bonding near the active site, confirming N-terminal displacement in solution.\",\n      \"method\": \"NMR amide proton line-broadening with paramagnetic Gd-EDTA probe, hydrogen exchange assays\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structural mapping in solution corroborated by crystal structure\",\n      \"pmids\": [\"9657677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TIMP-1 inhibits ADAM-10 with an apparent inhibition constant of ~0.1 nM, whereas TIMP-2 and TIMP-4 cannot inhibit ADAM-10; TIMP-3 inhibits ADAM-10 with Ki ~0.9 nM. This selectivity distinguishes ADAM-10 from TACE (ADAM-17), which is inhibited only by TIMP-3, providing a tool to differentiate the two sheddases in cell-based assays.\",\n      \"method\": \"Quenched fluorescent substrate assay and myelin basic protein degradation assay with recombinant ADAM-10 Fc fusion protein\",\n      \"journal\": \"FEBS Letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay with quantitative Ki determination, replicated with two substrates\",\n      \"pmids\": [\"10818225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The full-length N-terminal domain of TIMP-1 (N-TIMP-1) alone is insufficient to inhibit ADAM-10, in contrast to its inhibition of MMPs and ADAM-17 by TIMP-3 N-terminal domain; the C-terminal domain of TIMP-1 (or structural context beyond the N-terminal domain alone) is required for ADAM-10 inhibition.\",\n      \"method\": \"Inhibition assays comparing full-length TIMPs vs. isolated N-terminal domains against ADAM-10, ADAM-17, and MMPs\",\n      \"journal\": \"The Biochemical Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic in vitro inhibition assays with domain-deletion variants\",\n      \"pmids\": [\"18215140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"TIMP-1 (and TIMP-2) stimulate cell proliferation via tyrosine kinase-dependent signaling: tyrosine kinase inhibitors (genistein, erbstatin, herbimycin A) block TIMP-1-induced [3H]thymidine incorporation, while PKC and PKA inhibitors do not; TIMP-1 treatment elevates phosphotyrosine-containing proteins and activates MAP kinase, establishing a growth-signaling pathway independent of MMP inhibition.\",\n      \"method\": \"[3H]Thymidine incorporation, selective kinase inhibitors, phosphotyrosine immunoblotting, MAP kinase activity assay in MG-63 osteosarcoma cells\",\n      \"journal\": \"FEBS Letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal pharmacological and biochemical methods in one study\",\n      \"pmids\": [\"8906876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TIMP-1 activates Ras (increases Ras-GTP) via a tyrosine kinase (TYK)/MAPK pathway (herbimycin A-sensitive), whereas TIMP-2 activates Ras through a PKA-mediated pathway (H89-sensitive); the two TIMPs thus use distinct upstream signaling routes to reach a common Ras effector, with TIMP-2 also promoting Ras-GTP/PI3K complex formation.\",\n      \"method\": \"Ras-GTP pull-down assay, selective kinase inhibitors (herbimycin A, H89) in MG-63 cells\",\n      \"journal\": \"Biochemical and Biophysical Research Communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical pull-down and pharmacological dissection; single lab\",\n      \"pmids\": [\"12147251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TIMP-1 inhibits apoptosis of activated hepatic stellate cells (HSCs) via MMP inhibition: a T2G mutant of TIMP-1 (selectively ablates MMP inhibitory activity) fails to prevent apoptosis, and synthetic MMP inhibitors also block HSC apoptosis, placing MMP inhibition upstream of the anti-apoptotic effect in HSCs.\",\n      \"method\": \"Site-directed mutagenesis (T2G mutant), synthetic MMP inhibitor treatment, apoptosis assays (serum deprivation, cycloheximide, nerve growth factor) in cultured HSCs and in vivo fibrosis model\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with functional apoptosis readout, corroborated in vivo\",\n      \"pmids\": [\"11796725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TIMP-1 activates cell survival signaling in human breast epithelial cells via focal adhesion kinase (FAK), PI3K, and ERK pathways independent of MMP inhibition: the T2G MMP-inactive mutant retains anti-apoptotic activity, synthetic MMP inhibitors do not protect these cells, and TIMP-1 still enhances survival in the presence of synthetic MMP inhibitors, revealing a cell-type-specific, MMP-independent signaling mechanism.\",\n      \"method\": \"T2G mutant, synthetic MMP inhibitor, TIMP-1 knockdown/overexpression, kinase pathway inhibitors, caspase activity assays in MCF10A breast epithelial cells\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis, pharmacological dissection, and loss-of-function with defined molecular readouts\",\n      \"pmids\": [\"12904305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CD63, a tetraspanin, was identified as a TIMP-1 cell-surface binding partner by yeast two-hybrid screening, confirmed by co-immunoprecipitation and confocal microscopy. CD63 co-localizes with TIMP-1 and integrin β1 on the cell surface; shRNA knockdown of CD63 reduces TIMP-1 cell-surface binding, abrogates TIMP-1-mediated integrin β1 activation and cell survival signaling, and restores normal polarization of breast epithelial cells in 3D matrigel, establishing CD63 as the functional receptor mediating TIMP-1's MMP-independent cytokine-like effects.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, confocal microscopy, shRNA knockdown, 3D matrigel polarization assay, integrin activation assays\",\n      \"journal\": \"The EMBO Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including Y2H, Co-IP, imaging, and functional KD with defined phenotype\",\n      \"pmids\": [\"16917503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TIMP-1's anti-apoptotic signaling in erythroid (UT-7) cells requires formation of a ternary complex: TIMP-1 binds specifically to proMMP-9 at the cell surface (silencing proMMP-9 abrogates TIMP-1 signaling), and proMMP-9 is anchored to the plasma membrane by CD44. The anti-apoptotic effect is MMP-independent (MMP-9-blocking antibodies and synthetic MMP inhibitors cannot replicate it), but these agents prevent TIMP-1 binding to proMMP-9, abolishing downstream JAK2/PI3K/Akt survival signaling.\",\n      \"method\": \"siRNA knockdown of proMMP-9 and CD44, function-blocking antibodies, synthetic MMP inhibitor, flow cytometry, binding/co-localization assays in UT-7 erythroid cells\",\n      \"journal\": \"The International Journal of Biochemistry & Cell Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple loss-of-function approaches with mechanistic epistasis establishing ternary complex requirement\",\n      \"pmids\": [\"19010442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The MMP-9·TIMP-1 complex binds LRP (low-density lipoprotein receptor-related protein) with high affinity, and LRP mediates cellular internalization and catabolism of MMP-9·TIMP-1 complexes; cells genetically deficient in LRP show diminished capacity for MMP-9·TIMP-1 catabolism, revealing LRP as a clearance receptor for the TIMP-1/MMP-9 complex.\",\n      \"method\": \"RAP (receptor-associated protein) antagonism, 125I-labeling internalization assays, LRP-deficient cell lines, in vitro binding assays\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — biochemical binding assays plus genetic loss-of-function with quantitative internalization readout\",\n      \"pmids\": [\"11279011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"In liver regeneration, TIMP-1 negatively regulates hepatocyte cell cycle progression by limiting HGF bioavailability: TIMP-1 loss-of-function (Timp-1−/− mice) accelerates expression of cyclin D1, PCNA, and phospho-histone H3, elevates MMP activity, increases active HGF in the ECM, and enhances phospho-Met and p38 signaling; conversely, TIMP-1 gain-of-function delays cell cycle progression.\",\n      \"method\": \"Timp-1−/− and transgenic overexpressing mice, real-time RT-PCR, HGF activity assays, immunostaining of cell cycle markers, partial hepatectomy model\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic gain- and loss-of-function with defined molecular mechanism (HGF/Met pathway)\",\n      \"pmids\": [\"15726641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Tumor cell-derived TIMP-1 maintains pro-metastatic Met signaling by inhibiting ADAM-10-mediated Met shedding: knockdown of tumor cell Timp-1 suppresses Met phosphorylation in metastatic foci and inhibits metastasis formation; conversely, knockdown of ADAM-10 triggers Met auto-phosphorylation and increased responsiveness to HGF, phenocopying Timp-1 overexpression.\",\n      \"method\": \"siRNA knockdown of Timp-1 and Adam-10 in syngeneic murine liver metastasis model, Met phosphorylation assays, HGF stimulation assays, tumor cell scattering assay\",\n      \"journal\": \"Clinical & Experimental Metastasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal epistasis knockdown experiments with defined molecular pathway in vivo and in vitro\",\n      \"pmids\": [\"21789719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TIMP-1 secreted by astrocytes promotes oligodendrocyte precursor cell (OPC) differentiation and CNS myelination via a mechanism independent of MMP inhibition: recombinant TIMP-1 increases NG2+ OPC numbers and O1+ mature oligodendrocyte numbers in a dose-dependent fashion, whereas the broad-spectrum MMP inhibitor GM6001 does not replicate this effect; TIMP-1 KO mice show delayed myelination and reduced white matter astrocytes.\",\n      \"method\": \"TIMP-1 KO mice, neurosphere cultures, A2B5+ immunopanned OPCs, recombinant TIMP-1 treatment, anti-TIMP-1 antisera, MMP inhibitor control (GM6001), developmental histology\",\n      \"journal\": \"The Journal of Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse, recombinant protein rescue, neutralizing antibody, and MMP-inhibitor control establishing MMP-independence\",\n      \"pmids\": [\"21508247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TIMP-1 acts as a chemoattractant for human neural stem cells (hNSCs) via CD63 and β1 integrin signaling: TIMP-1 binding to CD63 activates β1 integrin-mediated Akt and FAK phosphorylation and cytoskeletal reorganization; shRNA-mediated CD63 knockdown or β1 integrin blocking antibody abrogates TIMP-1-induced focal adhesion formation and migration.\",\n      \"method\": \"Microarray/proteomics identification, shRNA knockdown of CD63, β1-integrin blocking antibody, PI3K inhibition, focal adhesion and F-actin imaging, Boyden chamber migration assay\",\n      \"journal\": \"The Biochemical Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal loss-of-function approaches with defined signaling readouts\",\n      \"pmids\": [\"24635319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TIMP-1-mediated signaling via CD63 is necessary and sufficient to induce granulopoiesis and neutrophilia in mice: TIMP-1 variants that dissociate protease-inhibitory activity from CD63 binding reveal that the CD63-binding signaling domain alone drives bone marrow myeloid progenitor expansion and granulopoiesis; CD63 ablation abolishes both neutrophilia and TIMP-1-enhanced granulopoiesis.\",\n      \"method\": \"Systemic TIMP-1 elevation in mice, TIMP-1 domain-dissecting variants, BrdU pulse-labeling, CD63-null mice, bone marrow granulopoiesis-associated gene expression\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic receptor ablation and domain-dissecting variants with in vivo phenotypic readout\",\n      \"pmids\": [\"26001794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TIMP-1 mediates TGF-β-dependent crosstalk between hepatic stellate cells and HCC cells via FAK signaling downstream of its receptor CD63: TGF-β signaling in HSCs induces TIMP-1 secretion; TIMP-1 then activates FAK via CD63 on HCC cells, promoting their proliferation, motility, and survival; inhibition of TGF-β signaling (EW-7197) blocks TIMP-1 secretion and downstream FAK/Akt activation.\",\n      \"method\": \"Secreted protein identification from HSCs, CD63 interaction studies, FAK phosphorylation assays, orthotopic xenograft mouse model, pharmacological TGF-β receptor inhibition\",\n      \"journal\": \"Scientific Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway placement with in vivo validation; single lab\",\n      \"pmids\": [\"26549110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TIMP-1 promotes oligodendrocyte differentiation via a CD63/β1-integrin/Akt/β-catenin signaling axis: recombinant TIMP-1 activates Akt and stabilizes β-catenin in OPCs in a CD63- and β1-integrin-dependent manner; this trophic action is independent of TIMP-1's MMP-inhibitory function and is counteracted (but not abrogated) by Wnt7a-mediated canonical Wnt signaling.\",\n      \"method\": \"Recombinant TIMP-1 treatment of OPCs, CD63/β1-integrin blocking, Akt inhibitors, β-catenin reporter assays, Wnt7a co-treatment\",\n      \"journal\": \"Molecular Neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor blocking and pathway inhibition with defined differentiation readout; single lab\",\n      \"pmids\": [\"30121936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BRAFV600E drives TIMP-1 upregulation via NF-κB activation in papillary thyroid carcinoma: BRAF silencing in BCPAP cells decreases TIMP-1 expression and NF-κB binding activity; TIMP-1 then binds its surface receptor CD63, leading to Akt phosphorylation and anti-apoptotic/pro-invasive behavior. The BRAF→NF-κB→TIMP-1→CD63→Akt signaling axis is MEK-independent (sorafenib but not MEK inhibitors reduce TIMP-1 and Akt phosphorylation).\",\n      \"method\": \"BRAF gene silencing, specific MAPK/NF-κB inhibitors, TIMP-1 expression analysis, Akt phosphorylation assays, invasion assay in BCPAP cells\",\n      \"journal\": \"Endocrine-Related Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic silencing and pharmacological dissection with defined pathway; single lab\",\n      \"pmids\": [\"21903858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TIMP-1 promotes cell survival in breast cancer via a CD63/NOS2 pathway: TIMP-1 protein nitration and TIMP-1/CD63 co-immunoprecipitation occur at NO concentrations that induce PI3K/Akt/BAD pro-survival signaling; TIMP-1 antisense silencing blocks NO-induced PI3K/Akt/BAD phosphorylation in MDA-MB-231 cells.\",\n      \"method\": \"Antisense knockdown, co-immunoprecipitation of TIMP-1/CD63, immunohistochemistry, phosphorylation assays\",\n      \"journal\": \"PLoS One\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — Co-IP and loss-of-function with defined signaling readout; single lab\",\n      \"pmids\": [\"22957045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CD74 (invariant chain) was identified as a functional receptor for TIMP-1: co-immunoprecipitation and confocal microscopy confirmed TIMP-1-CD74 interaction; in silico docking (HADDOCK) predicted the N-terminal domain of TIMP-1 (N-TIMP-1) as the CD74 binding region, experimentally confirmed by showing recombinant N-TIMP-1 alone binds CD74; TIMP-1-CD74 interaction triggers intracellular ZAP-70 activation, and a synthetic peptide targeting the CD74 cytokine-binding site abrogates this activation.\",\n      \"method\": \"Ligand-receptor capture screening, co-immunoprecipitation, confocal microscopy, in silico docking (HADDOCK), recombinant N-TIMP-1 domain, ZAP-70 phosphorylation assays, blocking peptide\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — unbiased receptor screen confirmed by Co-IP, domain mapping, in silico docking, and functional signaling readout with blocking peptide\",\n      \"pmids\": [\"34391782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TIMP-1 interacts with Amyloid Precursor Protein (APP) and Amyloid Precursor-like Protein-2 (APLP2) as a novel receptor pair: unbiased ligand-receptor capture screening revealed this interaction, confirmed by pull-down assays and confocal microscopy; TIMP-1 triggers glucose uptake and proinflammatory cytokine expression in human monocytes via its C-terminal domain and through APP, establishing APP as a TIMP-1 receptor mediating proinflammatory monocyte activation.\",\n      \"method\": \"Unbiased ligand-receptor capture screening, pull-down assays, confocal microscopy, in silico docking, recombinant TIMP-1 C-terminal domain variants, glucose uptake assays, cytokine expression assays\",\n      \"journal\": \"The Journal of Cell Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — unbiased screen confirmed by multiple orthogonal assays with functional domain mapping\",\n      \"pmids\": [\"36629908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ADAMTS-7 directly degrades TIMP-1: in coimmunoprecipitation experiments the catalytic domain of ADAMTS-7 binds TIMP-1, which is degraded by ADAMTS-7 in vitro; ADAMTS-7 reduces TIMP-1's inhibitory capacity toward MMP-9, increasing net MMP-9 activity and collagen degradation in atherosclerotic plaques; Apoe−/−Adamts7−/− mice accumulate more Timp-1 and more collagen than Apoe−/− controls.\",\n      \"method\": \"Mass spectrometry of atherosclerotic plaques (Apoe−/−Adamts7−/− vs Apoe−/− mice), coimmunoprecipitation, in vitro degradation assays, FRET-based protein-protein interaction assay, immunofluorescence, picrosirius red staining\",\n      \"journal\": \"Circulation Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro degradation assay, Co-IP, FRET, and genetic mouse model with ECM readout\",\n      \"pmids\": [\"37675562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The human TIMP-1 gene contains transcriptional repressive elements: a region upstream of the basal promoter (−1718/−1458) represses reporter gene expression by ~50%, and the first intron strongly represses transcription from any promoter; deletion analysis and protein binding/mutational studies identified a repressive element at intron +684/+748 that binds Sp1, Sp3, and an unidentified Ets-related factor.\",\n      \"method\": \"Reporter gene constructs, deletion analysis, electrophoretic mobility shift assay (EMSA), mutational analysis, protein binding studies\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional promoter dissection with EMSA and mutational confirmation\",\n      \"pmids\": [\"11032844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Thrombin induces TIMP-1 gene transcription in human mesangial cells via STAT1 and STAT3: thrombin-induced STAT-DNA binding and TIMP-1 mRNA elevation are both blocked by STAT1 and STAT3 antisense oligonucleotides; supershift assays confirm STAT1 and STAT3 proteins are in the thrombin-induced DNA-binding complex.\",\n      \"method\": \"Northern blot, EMSA, supershift assay, antisense oligonucleotides in human glomerular mesangial cells\",\n      \"journal\": \"Kidney International\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — antisense knockdown of transcription factors with EMSA confirmation of DNA binding\",\n      \"pmids\": [\"11918744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TIMP-1 expression is a direct target of miR-1293: luciferase reporter assay with wild-type and mutant TIMP-1 3′UTR constructs showed miR-1293 inhibitor upregulates reporter activity; Western blot confirmed elevated TIMP-1 protein with miR-1293 inhibitor, establishing direct post-transcriptional regulation of TIMP-1 by miR-1293.\",\n      \"method\": \"Luciferase reporter assay with wild-type and mutant 3′UTR, Western blot, miR-1293 mimic and inhibitor co-transfection in 293T cells\",\n      \"journal\": \"Molecular and Cellular Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct 3′UTR luciferase assay with mutant control and protein-level validation\",\n      \"pmids\": [\"23943285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TIMP-1 induces pro-tumorigenic miR-210 upregulation in lung adenocarcinoma cells via a CD63/PI3K/Akt/HIF-1α-dependent pathway: TIMP-1 induces PI3K p110/p85 signaling and Akt phosphorylation, elevates HIF-1α protein, and upregulates HIF-1-regulated miR-210; downstream targets of miR-210 (FGFRL1, E2F3, VMP-1, RAD52, SDHD) are decreased; TIMP-1-containing exosomes accumulate miR-210 and promote HUVEC tube formation.\",\n      \"method\": \"Exogenous TIMP-1 treatment and TIMP-1 overexpression, PI3K/Akt inhibitors, HIF-1α monitoring, miR-210 quantification, target gene expression, exosome isolation and functional tube formation assay, in vivo xenograft\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple pathway inhibition experiments with in vitro and in vivo validation\",\n      \"pmids\": [\"25263437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TIMP-1 promotes cancer-associated fibroblast (CAF) accumulation and activates ERK1/2 signaling in prostate CAFs: TIMP-1 overexpression in xenograft models increases in vivo tumor growth and CAF accumulation; recombinant TIMP-1 enhances prostate CAF proliferation, migration, and ERK1/2 phosphorylation in vitro.\",\n      \"method\": \"TIMP-1 overexpressing constructs in xenograft mouse models (prostate and colon cancer), in vitro CAF proliferation/migration assays, ERK1/2 phosphorylation assays\",\n      \"journal\": \"PLoS One\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function in vivo and in vitro with defined kinase readout; single lab\",\n      \"pmids\": [\"24143225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TIMP-1 promotes colon cancer cell proliferation and metastasis via FAK-PI3K/AKT and MAPK signaling: TIMP-1 suppression decreases proliferation and metastasis while increasing apoptosis; mechanistic analyses confirm these effects are mediated through TIMP-1-specific regulation of FAK-PI3K/AKT and MAPK pathways in colon cancer cell lines.\",\n      \"method\": \"TIMP-1 knockdown and overexpression, proliferation/apoptosis/metastasis assays in vitro and in vivo (xenograft), FAK/Akt/MAPK phosphorylation assays, clinical specimen analysis (94 colon cancer cases)\",\n      \"journal\": \"Journal of Experimental & Clinical Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss- and gain-of-function with mechanistic pathway analysis; single lab\",\n      \"pmids\": [\"27644693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TIMP-1 reduces angiogenesis by restricting TIMP-1-free proMMP-9: in M2-polarized macrophages, downregulation of TIMP-1 produces TIMP-1-free proMMP-9 that is strongly angiogenic; re-complexing M2 proMMP-9 with exogenous TIMP-1 abolishes angiogenic activity; TIMP-1 silencing in M0/M1 macrophages renders them angiogenic; Mmp9-null M2 macrophages are nonangiogenic despite low TIMP-1.\",\n      \"method\": \"Macrophage polarization (M0/M1/M2), TIMP-1 ELISA, TIMP-1 siRNA silencing, in vivo angiogenesis assay, Mmp9-null murine macrophages, proMMP-9 reconstitution with exogenous TIMP-1\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal loss-of-function and reconstitution experiments with in vivo angiogenesis readout\",\n      \"pmids\": [\"24174628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"TIMP-1 inhibits stimulated bone resorption in a dose-dependent and reversible manner in vitro: recombinant TIMP-1 (and TIMP-2) blocked both PTH- and 1,25-dihydroxyvitamin D3-induced bone resorption in neonatal mouse calvarial cultures, without affecting protein synthesis, DNA synthesis, or cell viability markers.\",\n      \"method\": \"Neonatal mouse calvarial culture, PTH and vitamin D3 stimulation, dose-response with recombinant TIMPs, reversibility experiments\",\n      \"journal\": \"Biochimica et Biophysica Acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro assay with dose-response and reversibility control\",\n      \"pmids\": [\"8485170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"TIMP-1 inhibits endothelial cell migration through both MMP-dependent and MMP-independent mechanisms: MMP-dependent inhibition involves upregulation of VE-cadherin and PECAM-1 at cell-cell junctions; MMP-independent inhibition involves stimulation of PTEN expression with subsequent dephosphorylation of FAK (pY397) and paxillin, reduced F-actin stress fibers, and fewer focal adhesions.\",\n      \"method\": \"HDMVEC migration assay, synthetic MMP inhibitors (GM6001, MMP-2/9 inhibitor III), recombinant TIMP-1, VE-cadherin/PECAM-1/FAK/paxillin/PTEN immunostaining, F-actin cytoskeleton analysis\",\n      \"journal\": \"Experimental Cell Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection of MMP-dependent vs independent pathways with multiple molecular readouts\",\n      \"pmids\": [\"15530852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TIMP-1 inhibits proliferation and osteogenic differentiation of human bone marrow MSCs through the Wnt/β-catenin signaling pathway: TIMP-1 knockdown upregulates β-catenin and cyclin D1 and promotes osteogenesis; TIMP-1 overexpression attenuates Wnt3a-induced upregulation of cyclin D1 and RUNX-2, while TIMP-1 knockdown restores Dkk1-inhibited β-catenin and cyclin D1 expression.\",\n      \"method\": \"Stable TIMP-1 overexpression and knockdown in hBMSCs, osteogenic differentiation assays (Alizarin Red, ALP activity, qPCR), β-catenin/cyclin D1/RUNX-2 Western blotting, Wnt3a and Dkk1 epistasis experiments\",\n      \"journal\": \"Bioscience Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic gain- and loss-of-function with pathway epistasis; single lab\",\n      \"pmids\": [\"30473539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"EGF-induced secretion of TIMP-1 (and MMP-9) in extravillous trophoblasts requires activation of both PI3K and MAPK pathways: PI3K inhibitor LY294002 blocks Akt phosphorylation and abrogates TIMP-1 induction without affecting ERK; MEK inhibitor U0126 blocks ERK phosphorylation without affecting Akt; constitutively active Akt alone is insufficient to induce TIMP-1 secretion, placing TIMP-1 induction downstream of both pathways acting in parallel.\",\n      \"method\": \"PI3K inhibitor (LY294002), MEK inhibitor (U0126), constitutively active Akt constructs, RT-PCR, Western blot, zymography in HTR8/SVneo trophoblast cells\",\n      \"journal\": \"Reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological pathway dissection with genetic epistasis (constitutively active Akt)\",\n      \"pmids\": [\"15333786\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TIMP-1 is a two-domain secreted glycoprotein that inhibits virtually all MMPs and selected ADAMs (notably ADAM-10 but not ADAM-17) by inserting its N-terminal wedge-shaped edge into the MMP active-site cleft with Cys1 bidentately coordinating the catalytic zinc (Ki sub-nM, two-step slow tight-binding mechanism); independent of MMP inhibition, TIMP-1 acts as a cytokine via multiple cell-surface receptor complexes—including CD63/integrin β1 (activating FAK, PI3K/Akt, and ERK survival pathways), proMMP-9/CD44 (erythroid survival), CD74 (triggering ZAP-70 for proinflammatory monocyte activation), and APP/APLP2 (monocyte glucose uptake)—while upstream ADAMTS-7 can proteolytically degrade TIMP-1 to derepress MMP-9 activity, and intracellular TIMP-1 levels are regulated post-transcriptionally by miR-1293 and transcriptionally by an intron-1 repressive element binding Sp1/Sp3/Ets factors, STAT1/STAT3 (thrombin-induced), and NF-κB (TNFα/IL-6/BRAFV600E-induced).\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TIMP-1 is a secreted glycoprotein that functions both as a tight-binding inhibitor of metalloproteinases and as a cytokine-like signaling molecule operating through multiple cell-surface receptors. Its N-terminal domain mediates slow tight-binding inhibition of MMPs (Ki ~0.1 nM for MMP-1) and ADAM-10, though full-length TIMP-1 is required for ADAM-10 inhibition; this protease-inhibitory activity regulates HGF/Met bioavailability, collagen turnover, and hepatocyte proliferation during liver regeneration and ischemia-reperfusion injury [PMID:8798626, PMID:10818225, PMID:18215140, PMID:15726641, PMID:22407827]. Independently of MMP inhibition, TIMP-1 signals through the tetraspanin CD63 (via its C-terminal domain) in complex with β1-integrin to activate PI3K/Akt, FAK, and β-catenin pathways, driving granulopoiesis, neural stem cell migration, oligodendrocyte differentiation, and anti-apoptotic survival signaling in multiple cell types [PMID:26001794, PMID:24635319, PMID:30121936, PMID:22957045]. TIMP-1 additionally engages CD74 through its N-terminal domain to activate ZAP-70 in B lymphoma cells and binds APP/APLP2 through its C-terminal domain to stimulate glucose uptake and proinflammatory cytokine expression in monocytes [PMID:34391782, PMID:36629908].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Establishing the kinetic mechanism of MMP inhibition resolved how TIMP-1 achieves sub-nanomolar potency: a two-step slow tight-binding process involving an initial rapid encounter complex that isomerizes to a final tight complex, with the MMP C-terminal domain required for the fast binding step.\",\n      \"evidence\": \"In vitro kinetic analysis with recombinant TIMP-1 and full-length vs. C-terminal-truncated MMP-1\",\n      \"pmids\": [\"8798626\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinetics characterized only for MMP-1; generalizability to other MMPs not established\", \"No structural resolution of the isomerized tight complex\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"The discovery that TIMP-1 induces cell growth through tyrosine kinase and MAP kinase activation established that TIMP-1 possesses signaling activity beyond protease inhibition.\",\n      \"evidence\": \"Thymidine incorporation with tyrosine kinase inhibitors and MAP kinase activity assay in MG-63 osteosarcoma cells\",\n      \"pmids\": [\"8906876\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating signaling not identified\", \"Signaling observed in a single cell line\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"NMR mapping of the N-TIMP-1/MMP-3 interface revealed how the N-terminal domain displaces the MMP N-terminus and induces active-site conformational changes, defining the structural basis of inhibition.\",\n      \"evidence\": \"NMR spectroscopy with paramagnetic surface probing, validated against crystal structure\",\n      \"pmids\": [\"9657677\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interface characterized for MMP-3 only\", \"Dynamic aspects of the two-step binding mechanism not captured\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of ADAM-10 as a TIMP-1 target (Ki ~0.1 nM) expanded TIMP-1's inhibitory spectrum beyond MMPs to include a key sheddase, while confirming selectivity (no ADAM-17 inhibition).\",\n      \"evidence\": \"In vitro enzymatic assay with recombinant ADAM-10 catalytic domain and quenched fluorescent substrate\",\n      \"pmids\": [\"10818225\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ADAM-10 inhibition tested only with isolated catalytic domain, not full-length enzyme on cell surface\", \"Biological consequences of ADAM-10 inhibition not yet explored\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Mapping of transcriptional repressive elements in the TIMP-1 promoter and intron 1 (binding Sp1/Sp3 and an Ets-related factor) began defining the regulatory logic controlling TIMP-1 expression.\",\n      \"evidence\": \"Reporter gene deletion analysis and EMSA in cultured cells\",\n      \"pmids\": [\"11032844\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the Ets-related repressor not established\", \"In vivo relevance of intronic repressor not tested\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstration that TIMP-1 activates Ras-GTP through a tyrosine kinase/MAPK pathway (distinct from TIMP-2's PKA route) showed that individual TIMPs engage different upstream kinase cascades to converge on Ras.\",\n      \"evidence\": \"Ras-GTP pull-down with pharmacological inhibitors in MG-63 cells\",\n      \"pmids\": [\"12147251\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating Ras activation still unidentified\", \"Only tested in MG-63 cells\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of STAT1 and STAT3 as transcription factors mediating thrombin-induced TIMP-1 expression added a second tier of transcriptional regulation beyond AP-1 and NF-κB.\",\n      \"evidence\": \"STAT antisense oligonucleotides with EMSA/supershift in human mesangial cells\",\n      \"pmids\": [\"11918744\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct STAT binding sites in the TIMP-1 promoter not mapped\", \"Physiological significance in kidney disease not established\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Dissection of TIMP-1's anti-migratory activity in endothelial cells revealed dual mechanisms: MMP-dependent upregulation of junctional adhesion proteins and MMP-independent PTEN induction with FAK dephosphorylation, establishing TIMP-1 as a multi-modal migration regulator.\",\n      \"evidence\": \"Migration assays with recombinant TIMP-1 vs. synthetic MMP inhibitors, Western blotting for PTEN/phospho-FAK in HDMVEC\",\n      \"pmids\": [\"15530852\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor for MMP-independent PTEN induction not identified\", \"PTEN transcriptional vs. post-translational regulation by TIMP-1 not resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Reciprocal loss- and gain-of-function genetic models in mice established that TIMP-1 negatively regulates hepatocyte cell-cycle progression during liver regeneration by limiting HGF bioavailability and Met signaling.\",\n      \"evidence\": \"TIMP-1 knockout and transgenic mice with cell-cycle marker immunostaining and phospho-Met analysis after partial hepatectomy\",\n      \"pmids\": [\"15726641\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which MMP(s) mediate HGF activation in this context not defined\", \"Whether signaling through CD63 contributes in vivo not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Discovery that full-length TIMP-1 but not its isolated N-terminal domain inhibits ADAM-10 revealed that the ADAM-10 inhibition mechanism differs fundamentally from MMP inhibition and requires regions beyond the canonical N-terminal inhibitory domain.\",\n      \"evidence\": \"In vitro enzymatic inhibition assays with N-terminal domain constructs vs. full-length TIMP-1 against ADAM-10, ADAM-17, and MMPs\",\n      \"pmids\": [\"18215140\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which C-terminal residues contribute to ADAM-10 inhibition not mapped\", \"Structural basis of the requirement remains unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of a ternary TIMP-1/proMMP-9/CD44 signaling complex on erythroid cells showed that TIMP-1 co-opts its protease-binding partner proMMP-9 as a co-receptor to activate JAK2/PI3K/Akt survival signaling independently of MMP catalytic activity.\",\n      \"evidence\": \"Co-IP, siRNA knockdown of proMMP-9 and CD44, MMP function-blocking antibodies in UT-7 erythroid cells\",\n      \"pmids\": [\"19010442\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TIMP-1/proMMP-9 complex signals through CD44 mechanistically is unclear\", \"Whether CD63 also participates in erythroid signaling not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"TIMP-1 was shown to promote oligodendrocyte differentiation and CNS myelination through an MMP-independent mechanism, establishing a trophic role in the CNS distinct from its protease-inhibitory function.\",\n      \"evidence\": \"TIMP-1 KO neurosphere cultures rescued by recombinant TIMP-1 but not by GM6001 broad MMP inhibitor\",\n      \"pmids\": [\"21508247\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor and downstream pathway not identified in this study\", \"In vivo myelination rescue not demonstrated\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"In vivo and in vitro epistasis experiments showed that tumor-derived TIMP-1 maintains Met signaling by inhibiting ADAM-10-mediated Met ectodomain shedding, linking TIMP-1's ADAM-10 inhibitory activity to a pro-metastatic mechanism.\",\n      \"evidence\": \"Reciprocal siRNA knockdown of TIMP-1 and ADAM-10 in syngeneic liver metastasis mouse model with phospho-Met readout\",\n      \"pmids\": [\"21789719\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TIMP-1's signaling activity through CD63 also contributes to metastasis not dissected\", \"Therapeutic relevance of blocking TIMP-1/ADAM-10 not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"The BRAF(V600E)→NF-κB→TIMP-1→CD63→Akt signaling axis was defined in thyroid carcinoma, identifying CD63 as a functional receptor for TIMP-1 cytokine-like signaling and linking it to oncogenic survival.\",\n      \"evidence\": \"BRAF siRNA, MAPK inhibitors, TIMP-1/CD63 co-IP, and Akt phosphorylation in BCPAP cells\",\n      \"pmids\": [\"21903858\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct TIMP-1/CD63 binding affinity not quantified\", \"Contribution of MMP inhibition vs. signaling not fully separated\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"TIMP-1 deficiency in liver ischemia-reperfusion injury revealed that TIMP-1 protects hepatocytes by restraining MMP-9 activity, preserving c-Met signaling, and sustaining Akt/Bcl-2 pro-survival and cell-cycle pathways.\",\n      \"evidence\": \"TIMP-1 KO mice subjected to partial liver IRI with comprehensive signaling and cell-cycle marker analysis\",\n      \"pmids\": [\"22407827\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether exogenous TIMP-1 can rescue the KO phenotype not tested\", \"Relative contribution of MMP-9 vs. other MMPs not established\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"miR-1293 was identified as a direct post-transcriptional regulator of TIMP-1 via 3′UTR binding, adding a microRNA layer to TIMP-1 expression control.\",\n      \"evidence\": \"Luciferase reporter assay with wild-type/mutant TIMP-1 3′UTR and miR-1293 mimic/inhibitor in 293T cells\",\n      \"pmids\": [\"23943285\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological context and tissue specificity of miR-1293 regulation not established\", \"No in vivo validation\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defining TIMP-1's pro-migratory activity in neural stem cells through CD63/β1-integrin/Akt/FAK signaling established a complete receptor-to-cytoskeleton pathway for TIMP-1's MMP-independent trophic functions.\",\n      \"evidence\": \"CD63 shRNA, β1-integrin blocking antibody, PI3K inhibitor, focal adhesion counting in hNSCs\",\n      \"pmids\": [\"24635319\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether TIMP-1 directly binds CD63 or requires a co-receptor not resolved\", \"Mechanism linking Akt/FAK to cytoskeletal reorganization not detailed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Domain dissection in vivo demonstrated that TIMP-1's C-terminal domain (not the N-terminal MMP-inhibitory domain) is necessary and sufficient for CD63-dependent granulopoiesis, definitively separating the protease-inhibitory and cytokine functions to distinct structural domains.\",\n      \"evidence\": \"Systemic administration of TIMP-1 domain variants in CD63-KO and wild-type mice with BrdU labeling\",\n      \"pmids\": [\"26001794\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biophysical demonstration of C-terminal domain binding to CD63 not shown\", \"Whether granulopoiesis signaling uses the same Akt pathway as other CD63-dependent effects not confirmed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The CD63/β1-integrin/Akt/β-catenin pathway was shown to mediate TIMP-1's pro-differentiation effect on oligodendrocyte progenitors, completing the receptor-to-transcription circuit for the MMP-independent myelination role identified in 2011.\",\n      \"evidence\": \"CD63/β1-integrin blocking antibodies, PI3K inhibitor, Akt and β-catenin Western blotting in OPCs\",\n      \"pmids\": [\"30121936\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether TIMP-1 directly competes with Wnt ligands for β-catenin regulation not resolved\", \"In vivo myelination rescue through this pathway not demonstrated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Unbiased receptor screening identified CD74 as a second cytokine receptor for TIMP-1, bound via the N-terminal domain and activating ZAP-70, revealing that TIMP-1's two structural domains engage distinct receptors (CD74 via N-terminal, CD63 via C-terminal).\",\n      \"evidence\": \"Ligand-receptor capture, co-IP, confocal microscopy, domain mapping, blocking peptide, ZAP-70 phosphorylation in Namalwa B lymphoma cells\",\n      \"pmids\": [\"34391782\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biological outcome of TIMP-1/CD74/ZAP-70 signaling beyond kinase activation not defined\", \"Whether CD74 and CD63 cooperate or act in distinct cell types not explored\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"APP and APLP2 were identified as a third receptor system for TIMP-1 (bound via C-terminal domain), mediating monocyte glucose uptake and proinflammatory activation — expanding TIMP-1's cytokine receptor repertoire to three distinct surface receptors.\",\n      \"evidence\": \"Unbiased ligand-receptor capture, pull-down, confocal microscopy, domain variants, glucose uptake and cytokine assays in primary human monocytes\",\n      \"pmids\": [\"36629908\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling pathway from APP to glucose uptake not characterized\", \"Whether APP-mediated signaling is relevant in neuronal contexts not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"ADAMTS-7 was identified as a protease that directly degrades TIMP-1, reducing its MMP-9 inhibitory capacity and promoting collagen degradation in atherosclerotic plaques — establishing a proteolytic feedback mechanism that limits TIMP-1 activity.\",\n      \"evidence\": \"Mass spectrometry of plaques from Adamts7-KO/Apoe-KO mice, co-IP, in vitro degradation assay, FRET binding assay\",\n      \"pmids\": [\"37675562\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cleavage site(s) in TIMP-1 not mapped\", \"Whether ADAMTS-7 also affects TIMP-1's signaling functions not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: how the same TIMP-1 molecule coordinates simultaneous protease inhibition and receptor signaling in vivo; the structural basis for C-terminal domain engagement of CD63 vs. APP; whether CD63, CD74, and APP pathways interact or are mutually exclusive in specific cell types; and the full spectrum of TIMP-1's in vivo cytokine functions beyond granulopoiesis and myelination.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal structure of TIMP-1/CD63 or TIMP-1/APP complex\", \"No systems-level map of which receptor dominates in each tissue\", \"In vivo relevance of CD74/ZAP-70 axis unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 3, 4, 21]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [9, 15, 16]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 7, 12, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 3, 7, 9, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 7, 11, 12, 14, 15, 16]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [3, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [9, 16]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [10, 11]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CD63\",\n      \"CD74\",\n      \"APP\",\n      \"APLP2\",\n      \"ADAM10\",\n      \"MMP9\",\n      \"CD44\",\n      \"ADAMTS7\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"TIMP-1 is a secreted, disulfide-rich glycoprotein that functions both as a broad-spectrum inhibitor of matrix metalloproteinases (MMPs) and ADAM-10, and as a multifunctional cytokine that signals through several cell-surface receptor complexes to regulate cell survival, proliferation, differentiation, and migration. Its N-terminal wedge inserts into the MMP active-site cleft with Cys1 bidentately coordinating the catalytic zinc, achieving sub-nanomolar inhibition via a two-step slow tight-binding mechanism; inhibition of ADAM-10 uniquely requires the C-terminal domain [PMID:9288970, PMID:8798626, PMID:18215140]. Independent of MMP inhibition, TIMP-1 engages CD63/β1-integrin to activate FAK, PI3K/Akt, and ERK survival signaling, binds a proMMP-9/CD44 ternary complex on erythroid cells to trigger JAK2/PI3K/Akt, signals through CD74 to activate ZAP-70 in monocytes, and interacts with APP/APLP2 to drive monocyte glucose uptake and proinflammatory cytokine expression [PMID:16917503, PMID:19010442, PMID:34391782, PMID:36629908]. In vivo, TIMP-1 controls HGF bioavailability during liver regeneration, promotes oligodendrocyte differentiation in the CNS, drives granulopoiesis via CD63, and modulates angiogenesis by regulating the ratio of free to complexed proMMP-9 [PMID:15726641, PMID:21508247, PMID:26001794, PMID:24174628].\",\n  \"teleology\": [\n    {\n      \"year\": 1985,\n      \"claim\": \"Molecular cloning resolved TIMP-1's primary structure and established its identity with erythroid-potentiating activity (EPA), unifying two previously separate biological activities under one gene product.\",\n      \"evidence\": \"cDNA cloning and protein sequencing by two independent laboratories\",\n      \"pmids\": [\"3903517\", \"3839290\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No three-dimensional structure available\", \"Mechanism of metalloproteinase inhibition unknown\", \"Receptor for EPA activity unidentified\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Assignment of all six disulfide bonds defined the covalent framework that constrains the two-domain architecture critical for TIMP-1 function.\",\n      \"evidence\": \"Reverse-phase HPLC of proteolytic digests with Edman sequencing and FAB-MS\",\n      \"pmids\": [\"2163605\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Three-dimensional fold unknown\", \"Functional roles of individual disulfides not tested\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Kinetic analysis revealed TIMP-1 inhibits MMP-1 via a two-step slow tight-binding mechanism—a rapid initial complex (Kd ~8 nM) isomerizes to an extremely tight form (global Kd ~0.1 nM)—and showed the MMP C-terminal hemopexin domain is required for the fast first step.\",\n      \"evidence\": \"Time-course kinetic analysis with graphic, nonlinear regression, and numeric integration methods; comparison with truncated mini-collagenase\",\n      \"pmids\": [\"8798626\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of isomerization step unknown\", \"Generality to other MMPs not tested\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"The crystal structure of TIMP-1/MMP-3 revealed the canonical wedge-shaped inhibitory mechanism: Cys1 bidentately coordinates the catalytic zinc while Thr2 occupies the specificity pocket, explaining how a single inhibitor blocks diverse MMPs.\",\n      \"evidence\": \"X-ray crystallography of MMP-3 catalytic domain complexed with TIMP-1\",\n      \"pmids\": [\"9288970\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Conformational dynamics in solution not captured\", \"Basis of TIMP selectivity among MMPs incompletely explained\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"NMR-based solution mapping confirmed the crystallographic TIMP-1/MMP-3 interface and additionally revealed allosteric conformational changes in MMP-3 helix C upon TIMP-1 binding, extending the inhibitory model beyond the active site.\",\n      \"evidence\": \"NMR amide proton line-broadening with paramagnetic Gd-EDTA probe and hydrogen exchange assays\",\n      \"pmids\": [\"9657677\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional significance of allosteric changes in MMP-3 helix C untested\", \"Full-length TIMP-1 vs N-TIMP-1 comparison not performed\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"TIMP-1 was shown to signal as a growth factor—activating tyrosine kinase, MAP kinase, and phosphotyrosine cascades independently of MMP inhibition—establishing its dual identity as both protease inhibitor and cytokine.\",\n      \"evidence\": \"Thymidine incorporation, selective kinase inhibitors, phosphotyrosine immunoblotting, MAP kinase activity assay in MG-63 cells\",\n      \"pmids\": [\"8906876\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-surface receptor unknown\", \"MMP-independence not yet proven by mutagenesis\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Extending TIMP-1's inhibitory range beyond MMPs, quantitative enzymology showed TIMP-1 inhibits ADAM-10 at sub-nanomolar Ki but not ADAM-17, distinguishing these two sheddases pharmacologically.\",\n      \"evidence\": \"Quenched fluorescent substrate assay and MBP degradation assay with recombinant ADAM-10\",\n      \"pmids\": [\"10818225\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for ADAM-10 selectivity unknown\", \"Domain requirements for ADAM-10 inhibition untested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"LRP was identified as a clearance receptor for MMP-9·TIMP-1 complexes, providing a mechanism for systemic catabolism of the inhibitor–enzyme pair.\",\n      \"evidence\": \"125I-labeling internalization assays, RAP antagonism, and LRP-deficient cell lines\",\n      \"pmids\": [\"11279011\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether free TIMP-1 also binds LRP unclear\", \"In vivo significance for TIMP-1 levels not demonstrated\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"The T2G mutant (MMP-inactive) demonstrated that TIMP-1's anti-apoptotic effect in hepatic stellate cells is MMP-dependent, while in breast epithelial cells it is MMP-independent, revealing cell-type-specific signaling modes.\",\n      \"evidence\": \"T2G mutagenesis, synthetic MMP inhibitor comparison, apoptosis assays in HSCs and MCF10A cells; corroborated in vivo\",\n      \"pmids\": [\"11796725\", \"12904305\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating MMP-independent signaling in breast epithelial cells unknown at this point\", \"Structural determinants of the cytokine-like surface not mapped\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Genetic gain- and loss-of-function in mice revealed TIMP-1 negatively regulates hepatocyte cell cycle progression during liver regeneration by limiting HGF bioavailability through MMP inhibition.\",\n      \"evidence\": \"Timp-1−/− and transgenic overexpressing mice, partial hepatectomy, HGF activity assays, cell cycle marker immunostaining\",\n      \"pmids\": [\"15726641\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which specific MMPs cleave pro-HGF in this context not identified\", \"Whether TIMP-1's cytokine function also contributes unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"CD63 was identified as the cell-surface receptor for TIMP-1's MMP-independent signaling: CD63 knockdown abolished TIMP-1 binding, integrin β1 activation, cell survival, and epithelial polarization, establishing the CD63/β1-integrin axis.\",\n      \"evidence\": \"Yeast two-hybrid, co-immunoprecipitation, confocal microscopy, shRNA knockdown, 3D matrigel assay\",\n      \"pmids\": [\"16917503\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding site on TIMP-1 for CD63 not mapped\", \"Stoichiometry of CD63/integrin β1/TIMP-1 complex undefined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"A distinct ternary receptor complex—proMMP-9/CD44—was shown to mediate TIMP-1's anti-apoptotic signaling in erythroid cells via JAK2/PI3K/Akt, demonstrating that different cell types employ different TIMP-1 receptor assemblies.\",\n      \"evidence\": \"siRNA knockdown of proMMP-9 and CD44, function-blocking antibodies, flow cytometry in UT-7 cells\",\n      \"pmids\": [\"19010442\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether proMMP-9/CD44 and CD63 complexes coexist on the same cell untested\", \"Structural basis of TIMP-1/proMMP-9 interaction at the cell surface not resolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Domain-dissection showed the C-terminal domain of TIMP-1 is required for ADAM-10 inhibition—unlike MMPs which are inhibited by N-TIMP-1 alone—explaining differential domain requirements for metalloproteinase versus sheddase inhibition.\",\n      \"evidence\": \"Inhibition assays comparing full-length TIMP-1 vs N-TIMP-1 against ADAM-10, ADAM-17, and MMPs\",\n      \"pmids\": [\"18215140\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific C-terminal residues mediating ADAM-10 contact not identified\", \"No co-crystal structure of TIMP-1/ADAM-10\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Two independent studies established TIMP-1 as a paracrine regulator in specialized tissues: astrocyte-derived TIMP-1 promotes oligodendrocyte differentiation and CNS myelination (MMP-independent), while tumor-derived TIMP-1 maintains Met signaling by inhibiting ADAM-10-mediated Met shedding in metastatic foci.\",\n      \"evidence\": \"TIMP-1 KO mice and neurosphere cultures with GM6001 control (myelination); reciprocal Timp-1/Adam-10 knockdown in syngeneic liver metastasis model (Met signaling)\",\n      \"pmids\": [\"21508247\", \"21789719\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor for TIMP-1's MMP-independent trophic action on OPCs not yet identified at this time point\", \"Whether ADAM-10 inhibition is the sole mechanism maintaining Met in metastatic cells not excluded\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"TIMP-1 was shown to control angiogenesis by determining the ratio of TIMP-1-free to TIMP-1-complexed proMMP-9: M2 macrophages downregulate TIMP-1, releasing pro-angiogenic free proMMP-9, while re-complexing with exogenous TIMP-1 abolishes angiogenic activity.\",\n      \"evidence\": \"Macrophage polarization, TIMP-1 siRNA, in vivo angiogenesis assay, Mmp9-null macrophages, proMMP-9 reconstitution\",\n      \"pmids\": [\"24174628\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which free proMMP-9 promotes angiogenesis not fully resolved\", \"Relevance to tumor-associated macrophage biology in vivo not directly tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Domain-dissecting TIMP-1 variants in CD63-null mice proved that the CD63-binding signaling domain alone is necessary and sufficient for TIMP-1-driven granulopoiesis and neutrophilia, establishing in vivo functional separation of protease-inhibitory and cytokine activities.\",\n      \"evidence\": \"TIMP-1 domain variants, CD63-null mice, BrdU pulse-labeling, bone marrow gene expression\",\n      \"pmids\": [\"26001794\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise structural interface between TIMP-1 and CD63 not mapped at residue level\", \"Whether other TIMP-1 receptors contribute to hematopoiesis not excluded\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The downstream signaling pathway for TIMP-1-driven oligodendrocyte differentiation was delineated as CD63/β1-integrin→Akt→β-catenin stabilization, linking TIMP-1's cytokine function to Wnt pathway crosstalk in OPCs.\",\n      \"evidence\": \"Recombinant TIMP-1 treatment of OPCs, CD63/β1-integrin blocking, Akt inhibitors, β-catenin reporter, Wnt7a co-treatment\",\n      \"pmids\": [\"30121936\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab finding; independent replication needed\", \"Direct β-catenin stabilization mechanism not biochemically resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"CD74 (invariant chain) was identified as a third TIMP-1 receptor: the N-terminal domain of TIMP-1 binds CD74 and triggers ZAP-70 phosphorylation, establishing a proinflammatory signaling axis distinct from the CD63 and proMMP-9/CD44 pathways.\",\n      \"evidence\": \"Unbiased ligand-receptor capture, co-immunoprecipitation, confocal microscopy, in silico docking, recombinant N-TIMP-1, blocking peptide, ZAP-70 phosphorylation\",\n      \"pmids\": [\"34391782\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream transcriptional programs activated by TIMP-1/CD74/ZAP-70 not characterized\", \"Whether CD74 and CD63 compete for TIMP-1 binding unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"APP and APLP2 were identified as a fourth TIMP-1 receptor pair—mediated by TIMP-1's C-terminal domain—through which TIMP-1 drives glucose uptake and proinflammatory cytokine expression in monocytes, revealing yet another signaling axis.\",\n      \"evidence\": \"Unbiased ligand-receptor capture, pull-down assays, confocal microscopy, C-terminal domain variants, glucose uptake and cytokine assays\",\n      \"pmids\": [\"36629908\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling intermediates between APP and glucose uptake unknown\", \"Whether APP mediates TIMP-1 effects in neurons or other APP-expressing tissues untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"ADAMTS-7 was identified as a protease that directly degrades TIMP-1, derepressing MMP-9 activity and reducing collagen in atherosclerotic plaques—revealing a proteolytic mechanism that regulates TIMP-1 availability in vivo.\",\n      \"evidence\": \"Mass spectrometry of Apoe−/−Adamts7−/− vs Apoe−/− plaques, co-immunoprecipitation, in vitro degradation assays, FRET, immunofluorescence\",\n      \"pmids\": [\"37675562\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cleavage sites on TIMP-1 not precisely mapped\", \"Whether other ADAMTS family members also degrade TIMP-1 untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include: how TIMP-1 simultaneously engages multiple receptor complexes (CD63, proMMP-9/CD44, CD74, APP/APLP2) with apparently different domain surfaces; the atomic-resolution structure of TIMP-1/CD63 and TIMP-1/CD74 complexes; and the in vivo hierarchy and tissue specificity among these signaling axes.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-crystal structure of TIMP-1 with any of its cytokine receptors\", \"Relative contributions of each receptor pathway in specific tissues or disease contexts largely unknown\", \"Intracellular TIMP-1 functions, if any, remain uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 3, 4, 5, 6, 9, 32]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [7, 10, 11, 17, 18, 23, 24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 14, 25, 32]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [14, 25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [9, 14, 25, 32]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 10, 11, 17, 18, 21, 23, 24, 29]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [9, 10, 12]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [23, 24]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [16, 20]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"MMP3\",\n      \"MMP9\",\n      \"ADAM10\",\n      \"CD63\",\n      \"ITGB1\",\n      \"CD44\",\n      \"CD74\",\n      \"APP\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}